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Summary 
Gene transcription is a fundamental process of the living cell. Eukaryotic transcription 
of messenger RNA requires the regulated recruitment of the conserved transcribing 
enzyme RNA polymerase (Pol) II to the gene promoter. The most heavily regulated 
step is transcription initiation that involves the ordered assembly of Pol II, the general 
transcription factors (TF) -IIA, -IIB, -IID, -IIF, -IIE, -IIH and the co-activator 
Mediator complex. Mediator communicates between transcription regulators and Pol 
II, and is associated with human disease. Mediator from the yeast Saccharomyces 
cerevisiae (Sc) has a molecular mass of 1.4 megadaltons and contains 25-subunits that 
constitute a head, middle, tail and kinase module. The core of Mediator contains the 
head and middle modules that are essential for viability in Sc, and directly contact Pol 
II. Mediator co-operates with TFIIH, to assist assembly and stabilization of the 
transcription initiation complex and stimulate TFIIH kinase activity. Because of the 
large size and complexity of Mediator and the initiation machinery, the underlying 
mechanism remains poorly understood. In this work we studied the structure and 
function of Mediator head and middle modules, the structure of the reconstituted Pol 
II-core Mediator transcription initiation complex, and reveal mechanisms of 
transcription regulation.  
We report the crystal structure of the 6-subunit Schizosaccharomyces pombe 
Mediator head module at 3.4 Å resolution. The structure resembles the head of a 
crocodile and reveals eight elements that are part of three domains named neck, fixed 
jaw and movable jaw. The neck contains a spine, shoulder, arm and finger. The arm 
and essential shoulder elements contact the remainder of Mediator and Pol II. The 
head module jaws and central joint, important for transcription, also interact with 
Mediator and Pol II. The Sp head module structure is conserved and revises a 4.3 Å 
model of the Sc head module, explains known mutations, and provides an atomic 
model for one half of core Mediator. We further propose a model of the Mediator 
middle module based on protein crosslinking and mass spectrometry. 
To determine how Mediator regulates initiation, we prepared recombinant Sc 
core Mediator by co-expression of its 15 subunits in bacteria. Core Mediator is active 
in transcription assays and bound an in vitro reconstituted core initially transcribing 
complex (cITC) that contains Pol II, the general factors TFIIB, TBP, TFIIF, and 
promoter DNA. We determined the cryo-electron microscopy structure of the initially 
  iv 
transcribing core initiation complex at 7.8 Å resolution. The structure reveals the 
arrangement of DNA, TBP, TFIIB, and TFIIF on the Pol II surface, the path of the 
complete DNA template strand and three TFIIF elements. The ‘charged helix’ and 
‘arm’ of TFIIF subunit Tfg1, reach into the Pol II cleft and may stabilize open DNA. 
The linker region of TFIIF subunit Tfg2 extends between Pol II protrusion and TFIIB, 
and may stabilize TFIIB. The structure agrees with its human counterpart, and 
suggests a conserved architecture of the core initiation complex. Finally, we 
determined the cryo-electron microscopy architecture of the cITC-core Mediator 
complex to 9.7 Å resolution. Core Mediator binds Pol II at the Rpb4/Rbp7 stalk close 
to the carboxy-terminal domain (CTD). The Mediator head module contacts the Pol II 
dock and TFIIB ribbon and stabilizes the initiation complex. The Mediator middle 
module ‘plank’ domain touches the Pol II foot and may control polymerase 
conformation allosterically. The Med14 subunit bridges head and middle modules 
with a ‘beam’, and connects to the tail module that binds transcription activators 
located on upstream DNA. The ‘arm’ and ‘hook’ domains of core Mediator form part 
of a ‘cradle’ that may position CTD and the TFIIH kinase to stimulate Pol II 
phosphorylation. Taken together, our results provide a structural framework to 
unravel the role of Mediator in transcription initiation and determine mechanisms of 
gene regulation. 
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1 Introduction 
1.1 Transcription 
Gene transcription is the first step to interpret a genome’s content. During this process 
a DNA-dependent RNA polymerase synthesizes a RNA molecule that often serves as 
a template for protein translation. The polymerase enzyme is a multi-subunit machine 
featured in the three kingdoms of life1. Eukaryotes evolved three nuclear polymerases 
named RNA polymerase (Pol) I, II, and III that each produce a different class of 
RNA2. Pol I and III synthesize ribosomal 5.8S, 18S and 28S ribosomal RNA (rRNA) 
and non-translated RNAs such as tRNA and 5S rRNA, respectively. Pol II produces 
all protein-coding messenger RNA (mRNA) and other non-translated RNA species. In 
plants two additional polymerases, Pol IV and Pol V, synthesize RNA involved in 
gene silencing3. Mitochondrial and chloroplasts genomes are transcribed by dedicated 
single-subunit polymerases that most likely evolved from related phage enzymes4. 
 Although the different multi-subunit polymerases produce diverse RNA, their 
core demonstrates great structural conservation. The largest subunits of the bacterial 
polymerase, β and β’, show great homology to their archaeal and eukaryotic 
counterparts. Eukaryotic Pol I, II and III show a large degree of conservation in the 
polymerase subunits, associated transcription factors and the mechanism of 
transcription initiation2 (Table 1). All three nuclear polymerases are subject to 
regulation. A particularly complex network of accessory proteins has developed to 
enable precise regulation of Pol II that generates messenger RNA that serves as the 
template for protein synthesis. 
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Table 1 | Sc RNA polymerase subunits and initiation factors. Adapted from2. 
Pol I Pol II Pol III 
Polymerase Core   
A190 Rpb1 C160 
A135 Rpb2 C128 
AC40 Rpb3 AC40 
Rpb5 Rpb5 Rpb5 
Rpb6 Rpb6 Rpb6 
Rpb8 Rpb8 Rpb8 
A12.2 Rpb9 C11 
Rpb10 Rpb10 Rpb10 
AC19 Rpb11 AC19 
Rpb12 Rpb12 Rpb12 
Polymerase Stalk   
A14 Rpb4 C17 
A43 Rpb7 C25 
General Transcription Factors and Their Counterparts 
 Tfg1 C37 
 Tfg2 C53 
 Tfa1 C82 
 Tfa2 C34 
  C31 
TBP TBP TBP 
TAFs   
Rrn7 TFIIB Brf1 
Specific Factors   
  B 
 Rrn6  
 Rrn11  
SAGA   
TFIIH   
Mediator Rrn3  
 UAF  
  TFIIIC 
  SNAPc 
 
1.1.1 Pol II transcription cycle and regulation 
Transcription can be divided into five stages, pre-initiation, initiation, elongation, 
termination and recycling5 (Fig. 1). During pre-initiation Pol II and associated factors 
(Table 1) are recruited to the promoter and form the pre-initiation complex (PIC)6, the 
closed DNA is melted and the DNA template strand inserted into the active site5. 
Initiation begins with synthesis of the first RNA nucleotides. When the RNA reaches 
a length of 13-14 nucleotides Pol II transitions into the elongation phase that 
accompanies the exchange of initiation for elongation factors. When Pol II reaches the 
end of the gene, termination occurs that requires the association of termination 
Introduction 
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factors. The nascent RNA and Pol II are released, and Pol II is recycled and can carry 
out further rounds of transcription.  
Each step of the transcription cycle can be regulated by accessory proteins that 
interact with genomic DNA, nascent RNA, the Pol II core, and the Carboxy-terminal 
domain (CTD) of Pol II subunit Rpb15. The CTD is specific to Pol II and consists of 
an imperfect heptad repeat with the amino-acid sequence Y1S2P3T4S5P6S7. The 
hydroxyl groups of Y1, S2, T4, S5, and S7 are post-translationally modified during the 
transcription cycle7. These modifications are reversible and dynamic and give rise to a 
complex ‘CTD code’ that together with nascent RNA regulates the association of 
transcription factors8,9. Pol II can further be regulated by nucleic acids of particular 
secondary structure10-12. 
 
Figure 1 | Schematic of the transcription cycle. 
 
1.1.2 Pol II transcription initiation and general transcription factors 
Transcription initiation at eukaryotic protein-coding genes requires Pol II and the 
general transcription factors (GTF) TFIIA, -B, -D, -E, -F, and -H (Tables 1 and 2, Fig. 
2). In the canonical view of initiation6,13, promoter DNA first assembles with the 
TFIID subunit TATA-binding protein (TBP), TFIIB, TFIIA and the Pol II–TFIIF 
complex. TFIID enables promoter recognition and its subunit TBP binds the TATA-
box element that resides at a fixed distance of 25-30 nucleotides upstream of the 
transcription start site in most eukaryotes13. TBP bends promoter DNA up to 90° and 
enables TFIIB to bind in a unidirectional manner, defined by flanking B-recognition 
elements13. TFIIA may associate to stabilize the ternary complex on DNA. 
Subsequently, TFIIB aids to recruit Pol II-TFIIF, reaches into the Pol II active site, 
and helps position the transcription start and assists initial RNA synthesis14-16. The 
resulting core initiation complex (excluding TFIIA) is minimally required for in vitro 
Initiation
Elongation
Termination
Pre-initiation
Recycling
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transcription17 and subsequently binds TFIIE and TFIIH. TFIIE interacts with Pol II, 
GTFs and single-stranded DNA to stabilize the open complex. TFIIH subunit Ssl2 
unwinds promoter DNA using an ATP-dependent translocase18. The TFIIH kinase 
subunit Kin28 phosphorylates the Pol II CTD on S5 and to lesser extent S7 to pass a 
poorly understood initiation checkpoint8,9. The assembled initiation complex may 
undergo initial RNA synthesis that leads to the initially transcribing complex (ITC). 
After synthesis of the first 13-14 nucleotides the nascent RNA is predicted to clash 
with the TFIIB ribbon domain that occupies the RNA exit tunnel. This steric clash 
causes release of TFIIB, and later the release of general factors and formation of the 
elongation complex. After promoter clearance, TFIIA, TFIID, TFIIE and TFIIH may 
remain behind at the promoter as a ‘scaffold complex’ that facilitates additional 
rounds of initiation19. The order of assembly may differ in vivo20. 
 
Figure 2 | Schematic of the Pol II transcription initiation complex. Pol II and General 
Transcription Factors are indicated. TBP binds the TATA-box element. TFIID and TFIIB 
determine promoter directionality. Adapted from21. 
 
The general factor TFIIS assists in both initiation and elongation and reaches 
into the active site22. During initiation TFIIS facilitates PIC formation through 
unknown interactions23,24 and functionally co-operates with the Mediator co-activator 
complex to stimulate abortive transcription and productive elongation through the +1 
nucleosome, located downstream of the transcription start site25. Importantly TFIIS 
stimulates elongation26, and relieves unproductive Pol II states caused by 
backtracking or pausing through enzymatic cleavage of the RNA22,27. 
 
 
 
 
 
 
Pol II initiation complex
TFIIS
Pol II
TFIIH
TFIIE
TFIID
TFIIB
TFIIA
TFIIF
TBP
TATA
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Table 2 | General Transcription Factors of Sc Pol II. Adapted from28. 
Factor Subunits Function 
TFIIA 2 stabilizes the TFIID-DNA complex 
  
TFIIB 1 stabilizes the TFIID-DNA complex, imposes transcription 
directionally, helps recruit Pol II-TFIIF, assists in start site 
selection and initial transcription 
  
TFIID 14 consists of TBP and TBP-associated factors that aid in 
promoter recognition, interaction with transcription 
activators, co-activator complexes, and the +1 nucleosome 
  
TFIIE 2 helps recruit TFIIH, stimulates TFIIH kinase and ATPase 
activities and stabilizes open DNA by interacting with 
single-stranded DNA 
 
TFIIF 3 assists transcription start site selection, initial transcription 
and stabilizes the PIC 
  
TFIIH 10 facilitates promoter opening through ATP-dependent 
translocase, phosphorylates the CTD to assist promoter 
clearance, carries out DNA repair 
  
TFIIS 1 assists in PIC assembly and initial transcription, reaches into 
the Pol II active site to reduce pausing and backtracking 
during elongation 
1.1.3 Structural studies of transcription initiation 
Crystal structures of TBP in complex with DNA29, DNA-TFIIB	  cyclin domains30 and 
DNA-TFIIA31 revealed a minimal upstream DNA binding complex. Crystallographic 
analysis of Sc Pol II revealed the complete 12-subunit enzyme32. The position of the 
initiation factor TFIIB on Pol II was first investigated using 2D electron 
crystallography33. Subsequent biochemical crosslinking analysis from the Hahn group 
revealed that the TFIIB-ribbon bound close to the Pol II dock domain34 and was 
confirmed by crystallographic analysis of the binary Pol II-TFIIB complex35. A 
crystal of Pol II-TFIIB further revealed the position of the TFIIB N-terminal cyclin14-
16 and two TFIIB elements that reach into the Pol II active site and stabilize the DNA 
template strand16. The central dimerization domain of TFIIF36 was placed on Pol II 
using protein crosslinking analysis37,38. EM analysis by the Nogales group of human 
initiation complex intermediates revealed the cITC at low resolution and confirmed 
the general location of DNA, TBP, TFIIB and the TFIIF dimerization domain39. 
Further, TFIIF elements were observed that may reach into the Pol II cleft and contact 
TFIIB39. A recent model of the Sc cITC agrees with the human minimal PIC 
architecture40. The general factors TFIIE and TFIIH were reconstituted with the 
human PIC and visualized by EM. This revealed that TFIIE interacts extensively with 
the Pol II clamp and stalk domains and that TFIIH resides on downstream DNA39. 
Introduction 
 6 
The flexible TFIIH kinase module may reach towards the CTD substrate39. Two 
studies of the yeast Sc minimal PIC-Mediator head complex41 and complete Sc PIC42 
are inconsistent with current biochemical and structural findings43. Taken together, 
available evidence suggests that the transcription initiation complex is structurally and 
functionally conserved among eukaryotes43 (Fig. 2). 
1.2 The co-activator complex Mediator 
1.2.1 Early Mediator studies 
The in vitro reconstitution of transcription shed light on the role of the GTFs in basal 
transcription. However, the link between basal and activated transcription remained 
elusive44-46. The Young group initially identified suppressors of RNA polymerase B 
(SRB) that could rescue a cold-sensitive phenotype of Pol II CTD truncation47-49. It 
came as a great surprise when all SRB proteins and additional transcription regulators 
identified by earlier genetic screens50 were purified as a single multi-protein assembly 
in complex with Pol II from yeast cell extract51. This complex was named Mediator 
(Table 3), and the Pol II-Mediator complex was termed the Pol II holoenzyme. 
Improved preparations of Sc Mediator were obtained by pulldown using the classical 
transcription activators VP16, Gal4 and the Gal4-VP16 fusion protein, and gave first 
evidence of a direct activator-Mediator interaction45,51. Although early studies 
indicated that Mediator is required for activated transcription only, it has been 
demonstrated that Mediator facilitates basal transcription when GTFs are present in 
limiting amounts52. Mediator has since been established as a global53,54 and 
conserved55 transcription regulator. A comparative genomics analysis has revealed an 
evolutionarily conserved set of 17 Mediator subunits55. Several species-specific 
Mediator proteins have been identified that may serve additional regulatory 
functions56,57. 
1.2.2 Mediator function in transcription 
Mediator acts as a regulatory hub that integrates positive and negative transcription 
signals58. It has a central role in gene transcription and defects in Mediator are linked 
to human disease59.	   Mediator is recruited to enhancer and promoter regions by 
transcription activators60,61. Several activators can bind multiple Mediator subunits62, 
such as p53 that can associate with Med17 of the head module or Med1 of the middle 
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module63, leading to differential transcriptional output. The great majority of 
activators target tail module subunits60 and may permit a co-operative recruitment of 
Mediator to chromatin DNA. Activator binding may also affect Mediator 
conformation as suggested from EM studies of human Mediator in complex with 
VP16, the Sterol response element binding protein, Thyroid hormone receptor, 
Vitamin D receptor or p5363-65. Alternative Mediator conformations may facilitate Pol 
II recruitment to the promoter by providing a preferred interaction interface. The 
requirement for an activator transactivation domain can be overcome in vivo by 
artificial recruitment of Mediator66. The yeast Adr1-DNA-binding domain was fused 
to Mediator tail subunits Med3 or Med15 and thereby bypassed a need for the Adr1 
transactivation domain66. These findings suggest that the primary role of transcription 
activators is to recruit Mediator to enhancer/promoter DNA.	  
 Promoter-bound Mediator may subsequently recruit GTFs, Pol II, and other 
transcription regulators. Pol II purified from yeast whole cell extract revealed a Pol II-
TFIIF and Pol II-Mediator fraction67 and suggests a key role of Mediator is its ability 
to bind the polymerase enzyme and the CTD68. TFIIH assists promoter DNA melting 
and phosphorylates the CTD on serine 5 and 7 in vivo8. The TFIIH kinase is greatly 
stimulated in presence of Mediator45,68. A yeast two-hybrid screen from the Werner 
lab first showed a direct interaction between Mediator head module subunit Med11 
and TFIIH subunit Rad320. Chromatin-immunoprecipitation (ChIP) experiments 
suggest that Mediator, TFIIH, and TFIIE form a complex at several yeast promoters 
prior to Pol II-TFIIF association20. This pre-formed complex may resemble a re-
initiation competent scaffold that contains several GTFs and is stabilized by an 
activator19. Mediator facilitates recruitment of TFIIB52, and interacts with TFIID69 
and the TFIID subunit TBP70,71. Mediator co-operates with TFIIS during initiation23,24 
and assists transcription through the +1 nucleosome25. Altogether these results 
suggest a role of Mediator in the assembly and/or stabilization of the PIC.  
The reversibly associated Mediator kinase module regulates activated and 
repressive transcription. The kinase module subunit cdk8 was shown to phosphorylate 
other Mediator subunits, a histone tail, transcription factors and the TFIIH complex 
and can thereby regulate protein function72-74. The species-specific Mediator subunit 
Med26 is rarely observed in Mediator complexes that contain the kinase module75. 
This near mutually exclusive association has been suggested as evidence of a 
molecular switch. Structural and functional in vitro studies of yeast and human 
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Mediator complexes suggest an inhibitory function of the kinase module, by 
occluding the Pol II and/or CTD binding site on Mediator76-78. Regulation by the 
kinase module may include an activating function since it co-localizes with Mediator 
at active promoters61,79, interacts with the human elongation factor P-TEFb80, and can 
phosphorylate the CTD72.  
 
Table 3 | List of Sc Mediator modules and subunits. 
Module Subunit 
Head Med6 
 Med8 
 Med11 
 Med17 
 Med18 
 Med20 
 Med22 
Head/Middle Med19 
Middle Med1 
 Med4 
 Med7 
 Med9 
 Med10 
 Med21 
 Med31 
Head/Middle/Tail Med14 
Tail Med2/Med29 
 Med3/Med27 
 Med5/Med24 
 Med15 
 Med16 
Kinase Med12 
 Med13 
 CDK8 
 CycC 
Conserved Sc Mediator subunits are written in bold face.  
Subunits essential for yeast viability are underlined. Adapted from21. 
 
Mediator performs several post-recruitment functions in addition to its 
established role in PIC formation. Gdown1 is a human Pol II-associated protein that 
acts inhibitory on transcription initiation81-83. This repression can be relieved by 
Mediator and facilitates exchange for TFIIF to enable productive initiation complex 
formation84. DSIF, the human homologue of yeast Spt4/5, enhances transcription 
elongation processivity and confers Mediator-dependence in an in vitro transcription 
system with purified factors85. In higher eukaryotes up to seven additional Mediator 
subunits have been identified using mass spectrometry56,57 that may enable greater 
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regulatory control during transcription. Med23 was shown to affect alternative splice 
site selection through interaction with the hnRNP L particle86. Med25 may serve as an 
additional anchor for transcription activators87,88. Med26 may assist in the initiation-
elongation transition by facilitating exchange of TFIID for the super-elongation 
complex that contains P-TEFb89. Pulldowns of human Mediator coupled to mass 
spectrometry have identified a plethora of factors that may also interact with 
Mediator, such as the co-activator SAGA, RNA processing factors, histone modifiers, 
DNA repair components, and other chromatin-associated factors75. 
1.2.3 Structural studies of Mediator 
Yeast Sc Mediator is a 25-subunit of 1.4 MDa molecular mass. Mediator consists of 
biochemically defined head, middle, tail and kinase modules (Table 3). A detailed 
structural and functional understanding of Mediator is however lacking, due to large 
conformational flexibility, complex heterogeneity, and difficulty in preparation of 
large Mediator quantities. Single proteins and subassemblies have been studied at 
high-resolution using X-ray crystallography and Nuclear Magnetic Resonance (NMR) 
providing atomic structures for 20 % of Mediator21 (Fig. 3). 
  The Mediator complex has been investigated at low resolution using negative 
stain, cryo-negative stain and cryo-electron microscopy (EM)64,78,90-92 leading to a 
canonical view of its conserved modular architecture that was recently revised93,94. 
These studies suggest that Mediator has great intrinsic flexibility that may be 
important for its function as a transcription regulator. 
 The Mediator head module is the most highly conserved subassembly of 
Mediator and is composed of seven subunits, Med6, Med8, Med11, Med17, Med18, 
Med20, Med2255. The head module measures 223 kDa from Sc, and 197 kDa from 
Schizosaccharomyces pombe (Sp) respectively. Yeast two-hybrid screens and co-
immunoprecipitation demonstrated inter-subunit contacts in the Mediator head 
module95,96. Recombinant co-expression of the head module in insect cells97 enabled 
negative stain EM analysis of the head module71. This revealed three domains named 
neck, fixed jaw and movable jaw. Further it was shown that the movable jaw contains 
Med18/Med20. Bacterial co-expression of the Med8 C-terminus/Med18/Med20 
heterodimer enabled crystal structure solution of the movable jaw from Sc70 and Sp98. 
The Takagi and Kornberg groups solved the architecture of the complete Sc Mediator 
head module by crystallography to 4.3 Å resolution99. The structure revealed that the 
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fixed jaw contains the C-terminal regions of Med11/Med22/Med17, and that the neck 
contained Med6 and N-terminal regions of Med8/Med11/Med22/Med17. A separate 
study from the Cramer lab also identified the composition of the fixed jaw and 
revealed the N-terminal Med11/Med22 4-helix bundle at atomic resolution100. An 
atomic model of the complete head module was however lacking. 
 
Figure 3 | Known structures of Mediator subunits and subcomplexes. Mediator modules 
are colored (Head/light blue, Middle/violet, Tail/cyan, Kinase/grey, Species-specific 
subunits/metallic). The low-resolution head module model is shown as ribbon. Adapted 
from21. 
 
The Mediator middle module comprises seven subunits, Med1, Med4, Med7, 
Med9, Med10, Med21 and Med31. The Med7C/Med21101 and Med7N/Med31102 
subassemblies of the Mediator middle module were solved by crystallography. 
Additional subunit interactions have been identified using biochemistry and mass 
spectrometry tools95,96,103. A detailed model of the Middle module is nevertheless 
lacking, most likely due to a flexible character, revealed by native mass spectrometry 
and small-angle X-ray scattering103. 
The Mediator tail and kinase modules are less well understood. The tail 
module binds transcription regulators at enhancer and promoter regions and in Sc 
consist of Med2, Med3, Med5, Med15 and Med16. It is the evolutionary most diverse 
module and has acquired additional subunits in some species that may allow greater 
regulatory control. Structural work in yeast and human systems has focused on short 
transcription activator binding regions of the Med15104,105 and human-specific 
CycC/CDK8 (Hs)
7N/31 (Sc)
8C/18/20 (Sc) 
11N/22N (Sc)
7C/21 (Sc)
6/8/11/17/18/20/22 (Sc)
CycC (Sp)
15 ABD1
(Sc)
8C/18 (Sp)
15 KIX
(Hs)
15 KIX
(Sc)
1
NR2 Box
(Hs)
Tail
Middle Head
Kinase
25 ACID
(Hs)
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Med2587,88 subunits. The reversibly associated Mediator kinase module contains 
Cdk8, CycC, Med12, and Med13 and acts as both a positive and negative regulator of 
transcription76,77,79,80. The kinase Cdk8101 and the Cdk8/CycC106 dimer have been 
studied at high resolution. 
1.2.4 Studies of core Mediator and Pol II-Mediator complexes 
Biochemical experiments suggest that Mediator has a modular architecture and that 
modules may be functionally distinct. Mediator head and middle modules act together 
and are referred to as the core of Mediator (cMed)67, whereas Mediator tail and kinase 
modules may act independently107,108. cMed was initially identified through 
fractionation of yeast whole cell extract and mass spectrometry67, and has a human 
counterpart named positive cofactor 2109,110 that was recently reconstituted in vitro111. 
cMed further contains all subunits required for viability in yeast21. Purified Mediator 
head module bound to a minimal PIC97 that contained Pol II, TFIIB, TBP, TFIIF and 
DNA. However, the head module shows very little activity in vitro97 and the resulting 
head-minimal PIC was limited to a low resolution cryo-EM envelope41. A tail-less 
Mediator could be prepared by deletion of the Med14 C-terminal region (residues 1-
745) or of the Med16 subunit112. The ΔMed16 Mediator forms a complex with Pol II, 
indicating that the tail module is not required for Pol II binding91. Together these 
results indicate that Mediator head and middle modules form the core of Mediator and 
bind Pol II. 
The arrangement of the modules within Mediator was revised based on recent 
EM analysis93,94. EM also visualized endogenous Mediator in complex with Pol II at 
low resolution from yeast78,90,113 and human proteins114. These studies led to 
inconsistent locations of Mediator on Pol II, probably owing to Mediator 
heterogeneity and a lack of general factors. 
1.3 Structural biology methods 
The combination of three structural biology methods was required to reveal details of 
Mediator and transcription initiation described in this thesis, protein X-ray 
crystallography, EM, and protein crosslinking coupled to mass spectrometry.  
Protein X-ray crystallography enables the study of macromolecular structures 
at or near atomic resolution and has revealed many details of biology115. Structure 
determination requires an ordered three-dimensional array of the target molecule in a 
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crystal, subsequent irradiation using very bright x-rays, and the recording of resulting 
diffraction patterns. This pattern is related to the ordered lattice of atoms and 
electrons that interact with the incoming x-rays. This enables determination of the 
electron density and interpretation of the underlying atomic structure. 
EM enables imaging of macromolecules116. Negative stain EM is based on the 
displacement of a heavy atom solution by the target molecule. The dense shell of the 
molecule can be visualized at low resolution in an electron microscope. Cryo-EM 
directly visualizes the macromolecule and may therefore reveal details near atomic 
resolution. To this purpose the sample is applied to a grid and frozen in a thin layer of 
vitreous ice. The ideally randomly oriented particles are then imaged under low dose 
in an electron microscope. The single particle images are computationally aligned and 
their relative orientations determined. Backprojection of the two-dimensional images 
is then used to calculate an average three-dimensional reconstruction. A benefit of this 
method is the ability to separate heterogeneity to reveal either conformational or 
compositional differences. Recent advances in imaging and data processing make EM 
a powerful alternative to study large assemblies at high resolution116.  
Protein crosslinking coupled to mass spectrometry can define multi-protein 
architecture or pseudo-atomic models, when individual structures are known117. Free 
amine groups, lysine residues or the protein amino (N)-terminus, are covalently linked 
by chemical crosslinking. Protease digestion and mass spectrometric analysis of the 
resultant peptides allows the detection of crosslink sites within (intra) and between 
(inter) proteins. This provides low-resolution restraints of ~30 Å and is often used in a 
hybrid structural biology approach with EM, crystallography and modeling. 
1.4 Aims and scope 
Mediator bridges between transcription activators and the Pol II initiation 
machinery60. Though the role of Mediator in gene activation is likely ubiquitous53,54, 
its mechanism remains poorly understood. Structural and functional work has been 
hampered because the Mediator complex is not abundant in the cell, flexible, 
modular, and post-translationally modified. How does Mediator regulate transcription 
initiation? What is the structure of Mediator? How can Mediator interface with 
transcription regulators, general transcription factors and Pol II at the same time?  
Here we aimed to determine the high-resolution structure of the Mediator head 
module using X-ray crystallography. This work built on previous efforts to obtain 
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recombinant Mediator complexes by co-expression in bacteria21. The head module 
structure revealed a complex multi-protein assembly, explained genetic and 
biochemical data, and identified at least one head module element that is functional in 
transcription. We studied the architecture of the middle module by protein 
crosslinking and mass spectrometry. Subsequently we aimed to prepare the essential 
and conserved111 15-subunit core Mediator from recombinant material. We 
determined its architecture in complex with the cITC using EM to 9.7 Å resolution. 
We further obtained a reconstruction of the cITC to 7.8 Å resolution. This enabled 
fitting of known atomic models into the cITC and cITC-core Mediator densities. We 
extended our analysis to the middle module using crosslinking analysis. 
Complementary functional assays demonstrate regions of cMed that are important for 
transcription in vitro and in vivo. Finally, we reveal the architecture of cMed, how 
Mediator interacts with the initiation complex, how Mediator stimulates TFIIH 
phosphorylation of the Pol II CTD, and provide new evidence that Mediator exercises 
global control of transcription. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Bacterial strains 
Table 4 | Bacterial strains used in this study. 
Strain Description Source 
XL1- blue recA1 endA1 gyrA96 thi-1 hsdR17 supE4 relA1 lac(F’ 
proAB lacIqZΔM15Tn10(Tetr)) 
 
Stratagene 
BL21-(DE3)RIL B F- ompT hsdS(rB- mB-) dcm+ Tetr gal λ(DE3) endA The 
(argU ileY leuW Camr), extra copies of argU ileY and leuW 
tRNA genes on a COlE1-compatible plasmid with 
chloramphenicol resistance marker, protease deficiency, 
chromosomal T7-polymerase gene 
Stratagene 
Rosetta B834 (DE3) F- ompT hsdSB(rB- mB-) dcm+ metB, methionine auxotroph Novagen 
2.1.2 Yeast strains 
Table 5 | Yeast strains used in this study. 
Strain Genotype Source 
BY4741 MATa; his3D1; leu2D0; met15D0; Euroscarf 
Med17/med17Δ MATa; his3D1; leu2D0; met15D0; ura3D0 
srb4::KanMX 
Euroscarf 
MED17 shuffle - SRB4 MATa; his3D1; leu2D0; met15D0; ura3D0 
srb4::KanMX pRS315-SRB4 
this work 
MED17 shuffle - srb4-ts MATa; his3D1; leu2D0; met15D0; ura3D0 
srb4::KanMX pRS315-srb4-ts 
this work 
MED17 shuffle -
med17Δ321–369 
MATa; his3D1; leu2D0; met15D0; ura3D0 
srb4::KanMX pRS315-med17Δ321–369 
this work 
MED6/med6Δ MATa; his3D1; leu2D0; met15D0; ura3D0 
MED6::KanMX 
Euroscarf 
MED6 shuffle - MED6 MATa; his3D1; leu2D0; met15D0; ura3D0 
MED6::KanMX pRS315-MED6 
this work 
MED6 shuffle - 
med61–225 
MATa; his3D1; leu2D0; met15D0; ura3D0 
MED6::KanMX pRS315-med61–225 
this work 
MED6 shuffle - 
med6163-295 
MATa; his3D1; leu2D0; met15D0; ura3D0 
MED6::KanMX pRS315-med6163–295 
this work  
SHY349 MATa; ade2D; his3D; leu2D0; met15D; trp1D; 
ura3D; SRB5-Flag3::kanMx 
Steven Hahn 
MED7-TAP BY4743; YOL135C::kanMX4/YOL135C Euroscarf 
Y40343 W303; MATa; tor1-1; fpr1::NAT RPL13A-
FKBP12::TRP1 
Euroscarf 
Med18-FRB-KanMX6 W303; MATa; ade2-1; trp1-1; can1-100; leu2-3,112; 
his3-11,15; ura3; GAL; psi+; tor1-1 fpr1::NAT 
RPL13A-2xFKB12::TRP1 SRB5-FRB::kanMX6 
Euroscarf 
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2.1.3 Plasmids and oligonucleotides 
Table 6 | Plasmids used in this study. 
Vector Species Insert Type Res. Source 
LL322 Sp Med17-Med22-Med11 pCDFDuet Sm LL 
LL481 Sp Med20-Med18-Med8 pET21 Amp LL 
LL365 Sp Med17-Med22-Med11-Med6(C-6xHis)-
Med20-Med18-Med8 
pCDFDuet Sm LL 
CP001 Sp Med6 (1-180), N-6xHis pET28b Kan this work 
CP002 Sp Med6 (118-148), N-6xHis pET28b Kan this work 
CP003 Sp Med6 (118-180), N-6xHis pET28b Kan this work 
CP004 Sp Med6 (113-148), N-6xHis pET28b Kan this work 
CP005 Sp Med6 (113-180), N-6xHis pET28b Kan this work 
CP006 Sp Med8 (9-158) pET21d Amp this work 
CP007 Sp TBP, N-6xHis pET28b Kan this work 
CP008 Sp TBP (52-242), N-6xHis pET28b Kan this work 
CP009 Sp Med17 (77-545)-Med22-Med11 pCDFDuet Sm this work 
CP010 Sp Rpb4-Rpb7, C-6xHis pET24b Kan this work 
CP011 Sp Med8-Med18 pET21d Amp this work 
CP012 Sp Med17 (88-545) pCDFDuet Sm this work 
CP013 Sp Med17 (92-545) pCDFDuet Sm this work 
CP014 Sp Med17 (97-545) pCDFDuet Sm this work 
CP015 Sp Med17 (88-545)-Med22-Med11 pCDFDuet Sm this work 
CP016 Sp Med17 (92-545)-Med22-Med11 pCDFDuet Sm this work 
CP017 Sp Med17 (97-545)-Med22-Med11 pCDFDuet Sm this work 
CP018 Sp Med17ΔC-211 pCDFDuet Sm this work 
CP019 Sp Med17ΔN-77/ΔC-211 pCDFDuet Sm this work 
CP020 Sp Med8 (158-223) pET21b Amp this work 
CP021 Sp Med17ΔN97ΔC223 pCDFDuet Sm this work 
CP022 Sp Med17ΔN97Δloop1-3 pCDFDuet Sm this work 
CP023 Sp Med17ΔC223-Med11-Med22 (1-89) pCDFDuet Sm this work 
CP024 Sp Med17ΔC223-Med11(1-91)-Med22 (1-89)     pCDFDuet Sm this work 
CP025 Sp Med17ΔN97Δloop1-3-Med11-Med22 pCDFDuet Sm this work 
CP026 Sp Med17ΔN77ΔC223-Med11-Med22  pCDFDuet Sm this work 
CP027 Sp Med17ΔN77ΔC211-Med11-Med22 pCDFDuet Sm this work 
CP028 Sp Med18                       pET21b Amp this work 
CP029 Sp Med18, N-6xHis pET28b Kan this work 
LL394 Sc Med17-Med22-Med11-Med6-Med8-Med20-
Med18 
pETDuet Amp LL 
LL395 Sc Med19-Med14 (1-745), N-10xHis pET28b Kan LL 
LL451 Sc Med9-Med4-Med31-Med10-Med7-Med21 pCDFDuet Sm LL 
LL489 Sc Med17-Med22-Med11-Med6-Med8 (1-189) pETDuet Amp LL 
LL490 Sc Med17-Med22-Med1-Med8-Med18-Med20 pETDuet Amp LL 
LL534 Sc Med19-Med14 (1-745), N-10xHis pETDuet Amp LL 
LL535 Sc Med17-Med22-Med11-Med6-Med8-Med20-
Med18 
pCOLADuet Kan LL 
CP030 Sc Med19-Med14 (1-745) N-10xHis-SUMO pETDuet Kan this work 
CP031 Sc Med19-Med14 (1-745) N-10xHis- 
Gal4DBD(1-147)   
pETDuet Kan this work 
CP032 Sc Med9-Med4-Med31-Med10 pCDFDuet Sm this work 
CP033 Sc Med9-Med4-Med7-Med21-Med31 pCDFDuet Sm this work 
CP034 Sc Med9-Med4-Med10 pCDFDuet Sm this work 
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CP035 Sc Med17, C-Gal4DBD (1-147) pETDuet Amp this work 
CP036 Sc Med17 (90-687)-Med22-Med11-Med6-Med8-
Med18-Med20 
pETDuet Amp this work 
CP037 Sc Med17 (110-687)-Med22-Med11-Med6-Med8-
Med18-Med20 
pETDuet Amp this work 
CP038 Sc Med17 (150-687)-Med22-Med11-Med6-Med8-
Med18-Med20 
pETDuet Amp this work 
CP039 Sc Med17 (190-687)-Med22-Med11-Med6-Med8-
Med18-Med20 
pETDuet Amp this work 
CP040 Sc Med17 (227-687)-Med22-Med11-Med6-Med8-
Med18-Med20 
pETDuet Amp this work 
CP041 Sc Med17 (320-687)-Med22-Med11-Med6-Med8-
Med18-Med20 
pETDuet Amp this work 
CP042 Sc Med17 (417-687)-Med22-Med11-Med6-Med8-
Med18-Med20 
pETDuet Amp this work 
CP043 Sc Med19-Med14 (40-745), N-10xHis pET28b Kan this work 
CP044 Sc Med19-Med14 (77-745), N-10xHis pET28b Kan this work 
CP045 Sc Med19-Med14 (100-745), N-10xHis pET28b Kan this work 
CP046 Sc Med19-Med14 (130-745), N-10xHis pET28b Kan this work 
CP047 Sc Med19-Med14 (164-745), N-10xHis pET28b Kan this work 
CP048 Sc Med19-Med14 (204-745), N-10xHis pET28b Kan this work 
CP049 Sc Med17-Med22-Med11-Med6-Med8 (29-222)-
Med18-Med20 
pETDuet Amp this work 
CP050 Sc Med17-Med22-Med11-Med6-Med8 (59-222)-
Med18-Med20 
pETDuet Amp this work 
CP051 Sc Med17-Med22-Med11-Med6-Med8 (87-222)-
Med18-Med20 
pETDuet Amp this work 
CP052 Sc Med17, C-GAL4DBD(1-147)-Med22-Med11-
Med6-Med8-Med20-Med18 
pETDuet Amp this work 
CP053 Sc Med17, C-GAL4DBD(1-147)-Med22-Med11-
Med6-Med8-Med20-Med18 
pETDuet Amp this work 
CP054 Sc Med17 (1-320)-Med22-Med11-Med6-Med8-
Med20-Med18 
pETDuet Amp this work 
CP055 Sc Med17 (1-417)-Med22-Med11-Med6-Med8-
Med20-Med18 
pETDuet Amp this work 
Resistance, Res.; Sc, Saccharomyces cerevisiae; Sp, Schizozaccharomyces pombe; Kan, Kanamycin; 
Amp, Ampicillin; Sm, Streptomycin; cloned by Laurent Lariviére, LL. A detailed list of DNA 
oligonucleotides used for cloning can be obtained from the Cramer group. 
 
Table 7 | Oligonucleotides used for EM. 
Type Sequence (5’-3’) 
Template DNA  CGA GAA CAG TAG CAC GCT GTG TAT ATA ATA GTG TGT TGT 
ACA TAG CGG AGG TCG GTG GGG CAC AAC TGC GCT 
Non-template DNA AGC GCA GTT GTG CTA TGA TAT TTT TAT GTA TGT ACA ACA 
CAC TAT TAT ATA CAC AGC GTG CTA CTG TTC TCG 
RNA AUA UCA 
 
Table 8 | DNA used for transcription assays. 
Type Details Source 
Reverse transcription 
primer 
Sequence: 5’-Cy5-
TTCACCAGTGAGACGGGCAACAGCCAAGCTC-3’ 
Steven Hahn 
HIS4 yeast promoter Plasmid with 428 to +24 relative to start codon, pSH515 Steven Hahn 
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2.1.4 Antibodies 
Table 9 | Antibodies used in this study. 
Antibody Dilution Host Source 
anti-Rpb3 1:2,000 rat NeoClone  (1Y26) 
anti-Ser5-P 1:20 mouse D. Eick (Helmoltz-Zentrum-München, 3E10) 
anti-rat IgG HRP 1:3,000 goat Sigma (A9037) 
anti-mouse IgG HRP 1:3,000 goat Bio-Rad (170-6516) 
anti-TFIIB 1:4,000 rabbit Abcam (ab63909) 
anti-TBP 1:400 rabbit Santa Cruz (sc-33736) 
anti-Med17 1:10,000 rabbit Steven Hahn (Fred Hutchinson Cancer 
Research Center) 
anti-Flag-tag 1:1,000 mouse Sigma (F1804) 
anti-Med2 1:1,000 goat Santa Cruz (sc-28058) 
anti-rabbit IgG HRP 1:3,000 goat Santa Cruz (sc-2004) 
anti-goat IgG HRP 1:3,000 donkey Santa Cruz (sc-2020) 
2.1.5 Growth media and additives 
Table 10 | Growth media for E. coli and S. cerevisiae cultures. 
Media Organism Description 
LB E. coli 1 % (w/v) tryptone, 0.5 % (w/v) yeast extract. 0.5 % (w/v) NaCl 
SeMet E. coli 22 g/L SeMet base, 5g/L nutrient mix, 40 µg/mL SeMet 
(Molecular Dimensions) 
YPD S. cerevisiae 2 % (w/v) peptone, 2 % (w/v) glucose, 1 % (w/v) yeast extract 
 
Table 11 | Additives for E. coli cultures. 
Additive Application Stock solution Applied concentration 
Ampicillin Antibiotic  100 mg/mL in H2O 0.1 mg/L 
Kanamycin Antibiotic 20 mg/mL in H2O 0.02 mg/L 
Streptomycin Antibiotic 30 mg/mL in H2O 0.03 mg/L 
Chloramphenicol Antibiotic 30 mg/mL in Ethanol 0.03 mg/L 
IPTG Protein expression 1 M in H2O 0.5 mM 
isopropyl-b-D-thiogalactoside, IPTG. 
2.1.6 General buffers and solutions 
Table 12 | List of general buffers and solutions. 
Name Description Application 
Electrophoresis buffer 10x MOPS NuPAGE buffer (Life 
Technologies) 
SDS-PAGE 
5x SDS loading dye 250 mM Tris pH 6.8, 50 % Glycerol, 0.03 % 
bromophenol blie, 7.5 % SDS, 100 mM DTT 
SDS-PAGE 
SDS-PAGE stain Instantblue (Expedion) SDS-PAGE staining 
Transfer buffer NuPAGE TransferBuffer (Life Technologies) Western blot 
PBS buffer 137 mM NaCL, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.76 mM KH2PO4, 0.1 % Tween 
20, pH 7.4  
Western blot 
100x PI 0.028 mg/mL Leupeptin, 0.137 mg/mL 
Pepstatin A, 0.017 mg/mL PMSF, 0.33 
mg/mL Benzamidine in Ethanol 
Protease Inhibitor 
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PMSF 100 mM phenylmethanesulfonylfluoride 
(Sigma-Aldrich) stock solution, in 100 % 
DMSO 
Protease Inhibitor 
ABESF 100 mM 4-(2-Aminoethyl) benzenesulfonyl 
fluoride hydrochloride (Sigma-Aldrich) stock 
solution, in H2O 
Protease Inhibitor 
10x TAE 50 mM EDTA pH 8, 2.5 M Tris-acetate Agarose gel 
10x TBE 900 mM Tris, 900 mM boric acid, 20 mM 
EDTA, pH 8.0 
Transcription assay 
2x ssRNA loading dye 20 % 10x TBE, 8 M RNase free urea, 0.03 % 
bromopehnol blue, 0.03 % xylene caynol FF 
Transcription assay 
5x transcription buffer 500 mM K Acetate, 100 mM Hepes pH 7.6, 
5mM EDTA pH 8, 25mM Mg Acetate 
Transcription assay 
5x primer annealing buffer 25mM Tris pH 8.3, 375mM KCl, 5mM 
EDTA pH 8.0 
Transcription assay 
5x synthesis buffer 25 mM Tris pH 8.3, 375 mM KCl, 22.5 mM 
MgCl2, 75 mM DTT 
Transcription assay 
TBE-Urea-PA Gel solution 8% acrylamide NF(40%/2% solution), 1x 
TBE buffer, 7 M Urea, filtered and degassed 
Transcription assay 
 
2.2 Methods 
2.2.1 Molecular Cloning 
Cloning strategy 
Expression constructs were designed based on previous multi-protein cloning 
strategies70,101. A T7 promoter controlled by the Lac Repressor was placed before 
each open reading frame (ORF) or sum of ORFs, when the total length did not exceed 
~2,000 basepairs. Sequential ORFs were separated by 20-50 basepairs. Each coding 
region was preceded by a ribosomal binding sequence six nucleotides from the start 
codon as described101. Known binding partners were cloned in sequence, generally 
under control of the same T7 promoter. For co-expression with multiple plasmids, 
antibiotic resistance, the origin of replication, and plasmid copy number were taken 
into account. 
 
Polymerase Chain Reaction (PCR) 
PCR primers were designed to contain a GC-rich 5’-overhang, an appropriate 
restriction site, and 18 or more nucleotides complementary to the sequence of 
interest101. PCR was performed with the Phusion High-Fidelity DNA Polymerase 
(Finnzymes), in a 50 µL reaction volume. DNA plasmids (Table 6), PCR products, or 
yeast genomic DNA were used as the PCR template at 1-50 ng or 200 ng respectively. 
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0.5 pmol/µL PCR primers were used per reaction. Reactions were generally carried 
out in a Biometra T3000 Thermocycler with 25-30 thermocycles. Primer annealing 
temperature and synthesis time varied according to DNA template and primer. PCR 
products were visualized by agarose gel electrophoresis and Sybr Safe stain 
(Invitrogen), and purified using the QIAquick PCR purification kit (Qiagen). 
 
Restriction digest, dephosphorylation, and ligation 
Vectors and purified PCR products were cleaved using the appropriate restriction 
enzymes and reaction buffer (NEB) overnight at 37 °C. Treated vectors were 
dephosphorylated with FastaAP (NEB) and purified using the QIAquick PCR 
purification kit (Qiagen). When a complete ORF was replaced by restriction 
digestion, the cleaved vector was purified by agarose gel electrophoresis and the 
QIAquick Gel Extraction Kit (Qiagen). Ligation was carried out with a 5-fold molar 
excess of insert relative to vector using the Quick ligation kit (NEB). 
 
Transformation and sequencing 
For plasmid transformation in E. coli, a 50 µL aliquot of chemically competent cells 
(Table 4) was thawed on ice and incubated with 1 µL plasmid for 10 minutes. Cells 
were transformed by heatshock at 42 °C for 45 seconds and immediately transferred 
on ice to recover for two minutes. Subsequently 200 µL LB was added and cells were 
incubated at 37 °C for 1 hour in a thermomixer. Cells were then plated on LB agar 
plates that contained the appropriate antibiotic, and were incubated at 37 °C 
overnight. For sequencing, single colonies were used to inoculate 5 mL LB cultures. 
Plasmids were purified using the Mini Miniprep purification kit (Qiagen) and 
sequenced (GATC). For protein co-expression using three plasmids, multiple rounds 
of transformation were performed and chemical competence re-established between 
transformations. Typically two plasmids, carrying Kanamycin and Ampicillin 
resistance, were transformed first. To restore chemical competence, cells were 
incubated in 2 mL ice-cold 100 mM CaCl2 and 10 % Glcyerol for 30 minutes. Cells 
were then harvested by centrifugation, resuspended in 100 µL 100 mM CaCl2 and 10 
% Glcyerol and used for subsequent transformation. 	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2.2.2 General methods 
Protein expression and purification 
Proteins were expressed in E. coli and purified as indicated in the respective sections 
2.2.3, 2.2.4, and 2.2.5. Generally, proteins were express in 1-8 l LB culture volumes, 
from a 50-150 mL pre-culture. Cells were grown to the target OD600 and induced with 
IPTG for protein expression at 37 °C for 3-5 hours or at 18 °C overnight. 
Recombinant material was purified using tailored strategies that usually include 
affinity purification, ion exchange and size exclusion chromatography (see 2.2.3, 
2.2.4, and 2.2.5).  
 
Protein concentrating, determination of concentration, and storage 
Proteins were concentrated using AMICON Ultra spin concentrators (Millipore) using 
a molecular weight cutoff three-fold less than predicted for the target or as determined 
to recover most protein. Final protein concentration was determined by absorbance at 
280 nm using a NanoDrop spectrophotometer. Absorption coefficients were 
determined using ProtParam (http://expasy.org/tools/protparam.html). Purified 
proteins were flash-frozen in liquid nitrogen at stored at -80 °C. 
 
SDS-PAGE 
Proteins were visualized by SDS-PAGE analysis. The sample was incubated with 5x 
SDS-PAGE loading dye and heated to 95 °C for 3-5 min and loaded on a pre-cast 4-
12% NuPage gradient gel (Invitrogen). Gels were run using 1x MOPS buffer (Life 
Technologies) at 200 V for 45 minutes. For core Mediator, gels were run at 150 V for 
15 minutes and 200V for 35 minutes to better separate protein bands. Gels were 
stained with InstantBlue (Expedeon). 	  
Western blot 
Proteins were applied to SDS-PAGE and transferred to a nitrocellulose membrane 
(whatman protran BA83 membrane, GE Healthcare) soaked in 1x transfer buffer 
containing 20 % Ethanol. The transfer was done for 1.5 hours on ice at 30 V using the 
XCell II Blot Module according to manufacturer instructions (Life Technologies). 
After transfer the membrane was blocked with 5 % milk in 1x PBS for 30 minutes. 10 
mL of primary Antibody (Table 9) diluted in 5 % milk in 1x PBS were added and 
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incubated at 4 °C overnight. The membrane was washed four times in 30 minutes 
with 1x PBS and 10 mL secondary Antibody (Table 9), diluted in 5 % milk and 1x 
PBS, was applied and incubated for 30 minutes. The membrane was washed four 
times in 30 minutes with 1x PBS, developed using the Pierce enhanced 
chemiluminescence (ECL) western blotting substrate (Thermo Scientific), and imaged 
with an Advanced Fluorescence Imager (Intas). 
 
Protein identification 
Protein identification was carried out by mass spectrometry by the protein analysis 
core facility (Adolf-Butenandt-Institute, LMU) and Monika Raabe from the Urlaub 
group (Max Planck Institute for Biophysical Chemistry, Göttingen). 
 
Scaffold preparation 
Oligonucleotides that comprise the DNA-RNA scaffold for EM (Table 7) were 
dissolved separately in 1x TE at a concentration of 400 µM. Dissolved DNA and 
RNA were mixed in equimolar amounts (100 µM final concentration) and annealed in 
a Biometra T3000 Thermocycler that heated to 95 °C and cooled in 1 °C increments 
every 30 seconds until 10 °C were reached. Annealed scaffold was stored at -20°C. 
 
Initial protein crystallization 
Initial protein crystallization screens were performed at the MPI crystallization 
facility (Max Planck Institute of Biochemistry, Martinsried). On average eight 96-
well sitting drop sparse matrix screens were used to identify initial crystallization 
conditions, from commercial or in house source including Complex (QIAGEN), 
Complex 2 (QIAGEN), Ammonium Sulphate (QIAGEN), Crystal platform Magic 1 
(in house), Crystal platform Magic 2 (in house), Anions (QIAGEN), Cations 
(QIAGEN), Classics (QIAGEN), Cryos (QIAGEN), PEGs (QIAGEN), and Index 
(Hampton). Screens were performed at room temperature or 4 °C, with 200 nL drop 
size (100 nL protein and 100 nL reservoir solution). Additive screens were performed 
using the Additive Screen HT (Hampton) with a customized the reservoir solution. 
Initial crystallization hits were optimized manually in 24- or 15-well hanging 
drop or 24-well sitting drop plates, or batch crystallization format. Generally, 1 µL 
reservoir buffer was added to 1 µL protein over a 600 µL reservoir solution at 20°C or 
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4°C. Total volume was varied from 2-8 µL. The ratio of protein to reservoir solution 
was varied between 1:1, 1:2, and 2:1. Seed stocks for micro-seeding were prepared 
with Seed Beads (Hampton) and appropriate seed stabilizing solution. For seeding, 2 
µL reservoir buffer was added to 1.5 µL protein, sealed and equilibrated for 30 min, 
before addition of 0.5 µL seeds. Seed stocks were frozen at -80°C and used multiple 
times. Crystal feeding was achieved by addition of purified Mediator head module (at 
3.5 mg/mL) to drops containing small head module crystals. To influence vapor 
diffusion rates, silicone and paraffin oils (Hampton) were added to the reservoir 
solution in different volumes (100-800 µL) and ratios (1:8-8:1). 
 
2.2.3 Specific methods for section 3.1 with focus on crystallography  
Vectors and sequences 
Vectors used in this section are shown in Fig. 5 and Table 6. Vectors containing a 
single T7 promoter are based on pET21, pET24 or pET28 vectors (Novagen). Vectors 
containing two T7 promoters are based on Duet vectors (Novagen). The head co-
expression vector that contains three T7 promoters was constructed by concatenating 
two Duet vectors. Open reading frames (ORFs) were cloned sequentially into vectors. 
For polycistronic constructs, ribosomal-binding sites were introduced as described101. 
Cells were grown in LB medium at 37 °C to an OD600 of 0.5 at 600 nm. Expression 
was induced with 0.5 mM isopropyl-β-D-thiogalactoside (IPTG) for 16 h at 18 °C. 
Sequence alignments were performed with MUSCLE118 and manually adjusted based 
on the presented structures. The graphical representation in Supplementary Fig. 1 was 
generated with ESPript119. 
 
Sp Med6 crystal structure determination 
For expression of Sp Med6 (residues 9–180), cells were transformed with the vector 
depicted in Fig. 5a and the protein was purified as described120 except that a HiLoad 
16/600 Superdex 200 pg (GE Healthcare) was used for size exclusion 
chromatography. Crystals were grown at 20 °C in hanging drops over reservoirs 
containing 100 mM HEPES, pH 7.5, and 400 mM sodium citrate. For crystallization 
of selenomethionine-labelled121 protein, sodium citrate was replaced by 16% (v/v) 
tacsimate. Crystals were collected, cryo-protected by gradually adding glycerol to a 
final concentration of 30% (v/v), and flash-frozen in liquid nitrogen. Native and 
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selenomethione single-wavelength anomalous dispersion (SAD) diffraction data were 
collected at 100 K on a PILATUS 6M detector at the X06SA beamline at Swiss Light 
Source (SLS), Villigen, Switzerland. Data were processed with XDS and 
XSCALE122. Phenix.autosol123 was used to detect selenium sites, phase the structure, 
perform density modification, and for initial model building. The model was manually 
adjusted using COOT124 and refined with Phenix.refine123, including high-resolution 
data125 because the resulting final model had a better Rfree value and stereochemistry. 
The refined structure has an Rfree value of 21.7% and shows very good 
stereochemistry (Supplementary Table 1). Ninety-six per cent of the residues fall in 
favoured regions of the Ramachandran plot and none of them are in disallowed 
regions126. 
 
Sc Med17C-Med11C-Med22C crystal structure determination 
Sc Med17C–Med11C–Med22C was expressed in cells co-transformed with the two 
vectors depicted in Fig. 5b and was purified as Sp Med6. For the Med11C–Med22C 
fusion construct, a linker with sequence GAGSGAGSG was inserted between the C 
terminus of Med11 and residue 96 of Med22. This covalent linker was essential for 
complex stability. Crystals were grown at 20 °C in hanging drops over reservoirs 
containing 100 mM MES, pH 6.0, and 4 M ammonium acetate. Crystals were 
collected, transferred to a solution containing 100 mM MES, pH 6.0 and 5 M 
ammonium acetate, and flash-frozen in liquid nitrogen. Selenomethionine labelling 
and diffraction data collection were as above for Sp Med6. Data were processed with 
XDS and XSCALE122. SHELXC/D/E127 was used to detect selenium sites, phase the 
structure, and perform density modification. The resulting electron density map 
allowed for building of most of the model with COOT124. The model was refined with 
Phenix.refine123, including high-resolution data125 because the resulting final model 
had a better Rfree value and stereochemistry. The refined structure has a Rfree value of 
23.3% and shows very good stereochemistry (Supplementary Table 1). Ninety-six of 
the residues fall in favoured regions of the Ramachandran plot and none of them is in 
disallowed regions126. 
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Preparation of recombinant Sc head module 
Sc head module was expressed in cells transformed with the single vector depicted in 
Fig. 5c. Cells were lysed by sonication in buffer A (50 mM HEPES-potassium 
hydroxide, pH 7.5, 400 mM potassium chloride, 10% (v/v) glycerol, 5 mM 
dithiothreitol (DTT)) containing protease inhibitors (Table 12). After centrifugation, 
the supernatant was loaded onto a 1 ml HisTrap column (GE Healthcare) equilibrated 
in buffer B (50 mM HEPES-potassium hydroxide, pH 7.5, 500 mM potassium 
acetate, 10% (v/v) glycerol, 50 mM imidazole, 5 mM DTT). The complex was eluted 
with a linear gradient from 50 mM to 300 mM imidazole in buffer B. The Sc head 
module was further purified by anion exchange chromatography with a 1 ml HiTrap 
Q HP column (GE Healthcare). The column was equilibrated in buffer C (50 mM 
HEPES-potassium hydroxide, pH 7.5, 150 mM potassium acetate, 10% (v/v) glycerol, 
2 mM DTT), and proteins were eluted with a linear gradient from 150 mM to 1.25 M 
potassium acetate in buffer C. Fractions containing head module were applied to a 
HiLoad 16/600 Superdex 200 pg (GE healthcare) size exclusion column equilibrated 
in buffer D (20 mM HEPES-potassium hydroxide, pH 7.5, 150 mM potassium 
acetate, 10% (v/v) glycerol, 2 mM DTT). The Sc head module was concentrated to 
5 mg ml−1, flash-frozen, and stored at −80 °C. The identity of the polypeptides was 
confirmed by mass spectrometry. Static light scattering showed that the complex 
contains one copy of each subunit (not shown). The Sc head module variant lacking 
the Med17 part of the joint (Med17∆321–369) was expressed and purified the same way. 
 
Yeast strains and functional assays 
Plasmids pRS316-SRB4 and pRS316-MED6 were generated by cloning the respective 
ORF plus 500 base pairs (bp) upstream and 300 bp downstream sequence into 
pRS316 (ATCC; URA3 marker). Plasmids pRS315-SRB4, pRS315-srb4ts, pRS315-
med17∆321-369, pRS315-MED6, pRS315-med61-225 and pRS315-med6163-295 were 
generated by cloning the respective wild-type or mutant ORF plus 500 bp upstream 
and 300 bp downstream sequence into pRS315 (ATCC; LEU2 marker). The 
heterozygous MED17/med17Δ and MED6/med6Δ Sc yeast strains were obtained from 
Euroscarf and transformed with pRS316-SRB4 and pRS316-MED6, respectively. 
Diploids were sporulated, tetrads were dissected and analysed, and a shuffle strain 
was selected. To assess functionality of mutants, pRS315 constructs were transformed 
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into the respective shuffle strain. Equal amounts of freshly grown yeast cells in SC 
(−Ura −Leu) medium were resuspended in water and tenfold dilutions were spotted 
on 5- fluoroorotic acid (5-FOA) and SC (−Ura −Leu) plates. Isogenic SRB4 and srb4ts 
strains used for nuclear extract preparation were obtained by transforming the MED17 
shuffle strain with plasmids pRS315-SRB4 or pRS315-srb4ts and streaking 
transformants twice on 5-FOA plates. Nuclear extracts were prepared from 3 l of 
yeast cultures as described19,100. In vitro transcription and analysis by primer 
extension were performed as described120. Primer extension was done a 5′-Cy5-
labelled oligonucleotide (Table 8) for all promoters. For activated transcription we 
added 200 ng of recombinant full-length Gcn4 that was purified as described120. HIS4 
and TMT1 template plasmids were as described120. The ACT1 template plasmid was 
generated by inserting the ACT1 promoter sequence (425 bp upstream to 24 bp 
downstream of the start codon) in pBluescript KS+ with HindIII and BamHI. 
 
Preparation of recombinant Sp head module 
The complete Sp head module was expressed in cells co-transformed with the three 
plasmids depicted in Fig. 5d. The crystallized Sp head module was expressed in cells 
co-transformed with the three plasmids shown in Fig. 5e. Cells were lysed by 
sonication in buffer E (20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10% (v/v) glycerol, 
5 mM DTT) containing protease inhibitors (Table 12). After centrifugation, the 
supernatant was precipitated with 35% (v/v) saturated ammonium sulphate, and 
pellets were resuspended in buffer E and loaded on a 2 ml Ni-NTA agarose beads 
column (QIAGEN) equilibrated in buffer E. The flow-through was reloaded on 
another 2 ml Ni-NTA column and both columns were washed with buffer E 
containing increasing concentration of imidazole (0, 10 and 20 mM). The complex 
was eluted from both columns with buffer E containing 300 mM imidazole. The His-
tag was cleaved overnight with 0.7 U thrombin (Sigma-Aldrich) per mg of protein 
while dialysing against buffer F (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM 
DTT). The complex was further purified by anion exchange chromatography using a 
HiTrap Q HP 1 ml column (GE Healthcare) equilibrated in buffer G (20 mM Tris-
HCl, pH 8.0, 50 mM NaCl, 10% (v/v) glycerol, 2 mM DTT) and eluted with a linear 
gradient from 50 mM to 500 mM NaCl in buffer G over 70 column volumes. 
Fractions containing the complex were collected and applied to a HiLoad 16/600 
Superdex 200 pg (GE Healthcare) size exclusion column equilibrated in buffer F. The 
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Sp head module was concentrated to 6 mg ml−1, flash-frozen and stored at −80 °C. 
The identity of the polypeptides was confirmed by mass spectrometry. 
 
Crystal structure determination of the Sp head module 
Crystals of the native complex were grown at 3.5 mg ml−1 Sp head module at 20 °C in 
hanging drops over reservoirs containing 50 mM MES, pH 6.0, and 1 M ammonium 
sulphate. Several treatments were required to obtain high-quality crystals, described 
in 2.2.2 (Initial protein crystallization). Crystals were collected and transferred in a 
stepwise manner to the final cryo-solution (50 mM MES, pH 6.0, 100% saturated 
lithium sulphate) and flash-frozen in liquid nitrogen. For structure solution native 
crystals were derivatized with Ta6Br12 (refs.128-130) (Proteros biostructures) and Yb-
DTPA-BMA131 (NatX-ray). Ta6Br12 was added directly to the crystallization drop at 
2 mM for 1 h. Yb-DTPA-BMA was added to the final cryo-solution at 100 mM for 
10 min and back-soaked 10 s before freezing. The Sp head module was further 
labelled with selenomethionine as described121. Crystals of the labelled protein were 
grown at 2 mg ml−1 Sp head module at 20 °C in hanging drops over a reservoir 
composed of 50 mM MES, pH 6.0, 0.95 M ammonium sulphate. Crystals were 
measured at 100 K at SLS, Villigen, Switzerland. Diffraction data were collected on a 
PILATUS 6M detector at the X06SA beamline (native crystals and Ta6Br12 and Yb-
DTPA-BMA derivatives) or on a PILATUS 2M detector at the X06DA beamline 
(selenomethionine-labelled crystals). Data were processed with XDS and 
XSCALE122. The HySS submodule in Phenix123 identified four heavy-atom sites in 
the Ta6Br12 derivative and a single heavy-atom site in the Yb-DTPA-BMA derivative. 
These sites were used as input for MIRAS phasing with autoSHARP132. Density 
modification was performed with Resolve133 and yielded an interpretable electron 
density map. In parallel, an anomalous difference Fourier map was calculated with 
data from selenomethionine-labelled crystals and with experimental MIRAS phases. 
The experimental map, in combination with the selenomethionine sequence markers, 
allowed the unambiguous manual fitting of the amino-terminal part of Med6 (residues 
10–117) and of the Med8C–Med18 subcomplex (PDB code 3C0T). Guided by 
knowledge of the folds and topologies of the Med11N–Med22N and Med17C–
Med11C–Med22C subcomplexes, we built a polyalanine model corresponding to all 
remaining secondary structure elements with COOT124. MIRAS phases were then 
combined with phases from this initial model and density was modified using the 
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AutoBuild routine in Phenix123. This led to an improved electron density map that 
allowed for an extension of the initial model. This process was iterated until no 
further improvement of the map was observed. Then, 23 selenium sites were 
identified and used as input for SAD phasing with the AutoSol routine in Phenix123. 
The new phases were combined with phases from the partial model. After density 
modification, an electron density map of excellent quality was obtained, in which 
many side chains and most of the linkers between secondary structure elements were 
visible. After rebuilding, the model was refined with autoBUSTER134. The resulting 
2Fo − Fc electron density map allowed further improvement of the model. After 
several rounds of rebuilding and refinement with autoBUSTER and Phenix.refine123 
using individual B-factor and TLS refinement, we obtained the final model, which 
shows good stereochemistry and a Rfree value of 25.8% (Table 13). Including high-
resolution data125 resulted in a refined structure with better Rfree values and 
stereochemistry. More than 95% and 99% of the residues fall in favoured and allowed 
regions of the Ramachandran plot, respectively126. 
 
Modeling of the Sc head module 
A hybrid model was built using our structure of Sc Med17C–Med11C–Med22C and 
the structure of Sc Med8C–Med18–Med20 (ref.70) as models for the fixed and 
moveable jaws, respectively. For the neck, our Sp head module was used, replacing 
Med11N and Med22 helix α1 with the corresponding Sc elements in the Sc Med11N–
Med22N structure100. Other amino acids of the neck were replaced with their Sc 
counterparts, based on sequence alignments. Hydrophobic character of the amino acid 
situated in the core in the resulting neck model was systematically checked. The 
obtained models for the two jaws, the spine and the shoulder were separately fitted 
onto the corresponding elements in the published architectural model of the Sc head 
module99 (PDB code 3RJ1), using secondary structure matching in COOT124. This 
resulted in a model that explained most of the published electron density. Regions of 
the model that lacked convincing density were removed, as well as side-chain atoms. 
The resulting model was adjusted by rigid-body refinement with Phenix.refine123, 
using the six structural elements present in the model (partial shoulder, partial arm, 
spine, tooth, nose and moveable jaw) as separate rigid-body groups. For figure 
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preparation and structure interpretation, Sp Med20 was modelled with 
MODELLER135. 
2.2.4 Specific methods for section 3.2 with focus on crosslinking  
Preparation of Sc 6-subunit middle module 
Bacterial co-expression of the Sc Mediator middle module was performed using a 
single plasmid based on a pCDFDuet-1 vector (Novagen), shown schematically in 
Fig. 13a. ORFs were cloned sequentially and additional ribosomal binding sites were 
introduced as described101. Med31 harbors a deca-histidine tag at its N-terminus. The 
exact sequence of the construct is available on request. The middle module was 
expressed in E. coli BL21 CodonPlus(DE3)RIL cells (Table 4). Cells were grown in 
LB at 37 °C to an optical density of 0.5 at 600 nm. Expression was induced with 0.5 
mM IPTG for 16 h at 18 °C. Cells were lysed by sonication in buffer H (50 mM Tris 
pH 8.0, 150 mM sodium chloride, 5 mM DTT) containing protease inhibitors (Table 
12). After centrifugation, the supernatant was loaded onto a 2 ml Ni-NTA agarose 
beads column (QIAGEN) equilibrated in buffer H. The column was washed with 
buffer H containing increasing concentration of imidazole (0, 20, 50 mM). The 
complex was eluted with buffer H containing 300 mM imidazole. The middle module 
was further purified by anion exchange chromatography with a 1 ml HiTrap Q HP 
column (GE Healthcare). The column was equilibrated in buffer I (50 mM Tris pH 
8.0, 50 mM sodium chloride, 2 mM DTT), and proteins were eluted with a linear 
gradient from 50 mM to 1 M sodium chloride in buffer I. Fractions containing middle 
module were applied to a HiLoad 16/600 Superdex 200 pg (GE healthcare) size 
exclusion column equilibrated in buffer J (20 mM HEPES-KOH pH 7.5, 150 mM 
potassium acetate, 10% (v/v) glycerol, 2 mM DTT). The protein complex was 
concentrated to 3 mg/ml, flash-frozen, and stored at -80 °C. 
 
Chemical protein crosslinking 
The pure middle module was cross-linked using isotopically coded 
cyanurbiotindipropionyl succinimide136 (CBDPS, Creative Molecules Inc.). The 
middle module was diluted to 0.5 mg/ml with buffer K (1x PBS, 2 mM DTT). 
CBDPS was dissolved in DMSO to 10 mM. To determine the optimal ratio of 
CBDPS to middle module, we mixed 3  µg of middle module with CBDPS at a 
concentration of 0.05–1.5  mM, and incubated for 30 min at 30 °C. The reaction was 
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stopped by addition of 0.5 M NH4HCO3 to a final concentration of 40  mM and 
incubation for 10  min at room temperature, and analyzed by SDS-PAGE (Fig. 13b). 
The optimum concentration of CBDPS was considered to result in a higher molecular 
weight band. We used a final concentration of 0.7  mM CBDPS. 
The cross-linked sample was dialyzed twice in dialysis buttons (Hampton 
Research) against 20 ml buffer K. Trypsin and/or GluC were respectively added in a 
1:10 or 1:1 ratio of protease to middle module and incubated overnight at 37 °C. 
Proteases were then inhibited by addition of 10 mM AEBSF and 20 mM PMSF, and 
incubation for 10 min at room temperature. Affinity enrichment was performed with 
monomeric avidin beads (ThermoFisher) equilibrated with 0.1 M ammonium acetate. 
The amount of bead slurry was adjusted to a ratio of 1:10 of total CBDPS to bead 
capacity (1.2 mg/ml). The sample was loaded five times. The column was washed 
with 300 µl ammonium acetate at concentrations of 0.1, 0.5, and 0.1 M, followed by 
three 300 µl H2O washes. The pH was adjusted to 2-3 by addition of 0.1% TFA. 
Peptides were eluted with buffer containing 0.1% TFA and 50% acetonitrile. The 
sample was concentrated to 10 µl by lyophilization. 
 
Mass spectrometry 
Mass spectrometric analysis was carried out with a nano-HPLC system (Easy-nLC II, 
ThermoFisher) coupled to the ESI-source of an LTQ Orbitrap Velos mass 
spectrometer (ThermoFisher Scientific). Samples were injected onto a 100 µm ID, 
360 µm OD IntegraFrit trap column (New Objective Inc.) packed with Magic C18AQ 
(5  µm particle size, 100 Å pore size, Bruker-Michrom) and desalted by washing for 
15 min at a flow rate of 300 nl/min with 0.1% (v/v) formic acid. Peptides were 
subsequently injected on a 75 µm ID, 360 µm OD IntegraFrit analytical column 
packed with Magic C18AQ (5  µm particle size, 100 Å pore size), equilibrated with 
95% solvent A (2% (v/v) acetonitrile, 98% (v/v) water, 0.1% (v/v) formic acid), 5% 
solvent B (90% (v/v) acetonitrile, 10% (v/v) water, 0.1% (v/v) formic acid). Peptides 
were separated at a flow rate of 300 nl/min using a 70 minutes gradient (0–60 min: 4–
40% solvent B, 60–62 min: 40–80% solvent B, 62–70 min: 80% solvent B). 
 MS data were acquired with Xcalibur (ver. 2.1.0.1140) with Mass Tags and 
Dynamic Exclusion precursor selection methods enabled in global data dependent 
settings. For CBDPS-H8/D8 mass difference between light and heavy isotopic forms 
of 8.05824 Da was used in Mass Tags setting. Mass Tags and inclusion list runs used 
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a Top 3 method. MS scans (m/z range from 400 to 2000) and MS/MS scans were 
acquired in the Orbitrap mass analyzer at 60000 and 30000 resolution, respectively. 
Fragment ions for MS/MS acquisition were produced by collision-induced 
dissociation (CID) at normalized collision energy of 35% for 10 ms at activation 
q=0.25. Data analysis was performed with DXMSMS Match of ICC-CLASS136. Two 
additional cross-link pairs (Med7(K35)–Med7(K103) and Med4(K36)–Med9(K117)) 
were obtained from a preliminary 7-subunit middle module preparation and were 
included in the final data set. 
 
Structure prediction and modelling 
Protein sequences of Med4, Med9 and Med10 from fungal species137 and higher 
eukaryotes were aligned with MUSCLE118. The generated alignments were used for 
structure prediction with HHPred138. Med4, Med9 and Med10 were predicted to be 
partly homologous to Med7, Med21 and Med8, respectively. 
For middle module modeling, the Sp Mediator head structure139 (PDB code 4H63) 
was used as a template. Sc Med11N/Med22N (PDB code 3R84) was superimposed on 
Sp Med11/Med22, either superimposing Sc Med22N on Sp Med11, or superimposing 
Sc Med22N on Sp Med22. Med7C/Med21 (PDB code 1YKH)101 was then 
superimposed on Sc Med11N/Med22N for both positions. Protein superimposition 
was performed using secondary structure matching in COOT124. A second 
Med7C/Med21 dimer was positioned in the same relative orientation as in the crystal, 
letting the open ends of the C-terminal coiled-coils interacting with each other101. The 
two resulting models, formed of Med8 and two copies of Med7C/Med21, were used 
as templates for final middle module modeling using MODELLER135. For this 
purpose, Med8 and the second copy of Med7C/21 served as templates for their 
structurally homologous regions in Med10 and Med4/9, respectively. 	  
2.2.5 Specific methods for section 3.3 with focus on EM 
Vectors and sequences 
Vectors for co-expression of Saccharomyces cerevisiae (Sc) core Mediator (cMed) 
subunits in Escherichia coli are shown in Fig. 17a. Open reading frames (ORFs) of 
Med19 and Med14 (1–745; ref.112) with an additional N-terminal 10×histidine tag 
were cloned sequentially into a pET Duet vector (Novagen, Table 6). The histidine 
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tags of previously cloned genes were removed139,140. Ribosomal binding sites were 
introduced as described101. Sequences are available upon request. All proteins were 
expressed in E. coli BL21(DE3)RIL (Stratagene). Mediator head and middle modules 
were expressed and purified as described in sections 2.2.3 and 2.2.4 (refs.139,140). 
 
Preparation of core Mediator 
For co-expression of the 15-subunit cMed, E. coli BL21(DE3)RIL cells were 
transformed with three plasmids (Fig. 17a) and grown in LB medium at 37 °C to an 
optical density of 0.7 at 600 nm. Expression was induced with 0.5 mM IPTG for 24 h 
at 18 °C. Cells were harvested and resuspended in buffer M (50 mM HEPES-KOH 
pH 7.5, 400 mM KCl, 10% glycerol, 10 mM imidazole, 5 mM DTT) containing 
protease inhibitors (Table 12). After sonication and centrifugation, the supernatant 
was loaded on a HisTrap HP 5 ml column (GE Healthcare) equilibrated in buffer N 
(25 mM HEPES-KOH pH 7.5, 400 mM KCl, 10% glycerol, 25 mM imidazole, 5 mM 
DTT). The column was washed with seven column volumes (CVs) of buffer N. The 
complex was eluted with a linear gradient from 25 mM to 300 mM imidazole in 
buffer N over 10 CVs. Fractions containing the complex were diluted 1:3 in buffer O 
(25 mM HEPES-KOH pH 7.5, 100 mM KCl, 10% glycerol, 1 mM EDTA, 5 mM 
DTT) and applied to a HiTrap Q HP 5 ml column (GE Healthcare) equilibrated in 
buffer O. The complex was eluted with a gradient from 100 mM to 800 mM KCl in 
buffer O over 25 CVs. Fractions containing the complex were concentrated and 
applied to gel filtration using a Superose 6 10/600 GL (GE Healthcare) equilibrated in 
buffer P (25 mM HEPES-KOH pH 7.5, 400 mM KCl, 3 mM DTT). Purified cMed 
was concentrated to 3 mg ml−1, flash-frozen and stored at −80 °C. Up to 2 mg of pure 
cMed could be obtained from 8 l cell culture (Fig. 16a). The identity of the protein 
subunits was confirmed by mass spectrometry. 
 
Promoter-dependent in vitro transcription 
Nuclear extract (NE) from 3 l yeast culture of strain SHY349 was prepared as 
described19,100. SHY349 NE was immuno-depleted of endogenous Mediator a s 
described19, with minor modifications. 150 µl NE were dialysed for 90 min against 
buffer Q (20 mM HEPES-KOH pH 7.6, 75 mM ammonium sulphate, 10 mM MgSO4, 
20% glycerol, 1 mM EGTA pH 8.0, 0.5 mM DTT) containing protease inhibitors 
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(Table 12). 75 µl anti-Flag M2 agarose beads (Sigma) were washed twice with buffer 
E, and incubated in NE for 1 h at 4 °C on a turning wheel. After centrifugation, the 
supernatant was depleted with the same amount of beads used initially. Beads were 
removed by centrifugation. The doubly depleted NE was flash-frozen and stored at 
−80 °C. Tandem affinity purification (TAP) of endogenous Mediator was performed 
using a C-terminal TAP tag on Med7 as described100. Purified TAP-Mediator was 
flash-frozen and stored at −80 °C. Activator-dependent and independent promoter-
dependent in vitro transcription and primer extension was performed as described100. 
Purified TAP-Mediator (~0.25 pmol), 7-subunit head module (1.25 pmol), 6-subunit 
middle module (1.25 pmol) or cMed (2.5 pmol) were added as indicated in Fig. 16b. 
 
Preparation of cITC–cMed complex 
S. cerevisiae 12-subunit Pol II141, TBP (residues 61–240)29, TFIIB16, and TFIIF 
(Saccharomyces mikatae Tfg1, S. cerevisiae Tfg2)37 were prepared as described. The 
nucleic acid scaffold previously used to generate the core Pol II initially transcribing 
complex (cITC)40, was used for assembly of the cITC–cMed complex (Table 7). Pol 
II (150 µg at 3 mg ml−1) was incubated with a fourfold molar excess of TFIIF for 
5 min at 25 °C. A twofold molar excess of nucleic acid scaffold and a fourfold molar 
excess of TBP and TFIIB were added to buffer R (25 mM HEPES-KOH pH 7.5, 
180 mM potassium acetate, 5% glycerol, 5 mM DTT) and incubated with pre-formed 
Pol II–TFIIF complex for 10 min at 25 °C. cMed was added to the cITC in a 1.2-fold 
molar excess over Pol II and incubated for 50 min at 25 °C. The sample was cooled in 
5 min intervals from 25 °C to 20 °C, 15 °C, 10 °C and 4 °C. The cITC–cMed complex 
was purified by gel filtration using a Superose 6 10/600 GL equilibrated in buffer R. 
Fractions containing the complex were concentrated to ~0.6 mg ml−1 and extra 
nucleic acid scaffold was added in equimolar amount. 
 
Binary interaction assays 
To test the binary interaction of cMed with glutathione-S-transferase (GST)–CTD, 
GST and GST–CTD were expressed separately in E. coli BL21(DE3)RIL cells and 
induced at an optical density of 0.5 at 600 nm with 0.5 mM IPTG. Cells were lysed by 
sonication in buffer S (20 mM HEPES-KOH pH 7.5, 100 mM KCl, 10% glycerol, 
100 µM EDTA, 0.1% NP40, 1 mM PMSF, 5 mM DTT). After centrifugation, the 
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supernatant was applied to 1 ml glutathione Sepharose 4B resin (GE Healthcare), 
equilibrated in buffer S. The resin was washed twice with 10 ml buffer S. 10 µg 
purified cMed were incubated for 3 h on ice with 30 µl immobilized GST or GST–
CTD resin. The resin was washed four times with 600 µl buffer G and bound proteins 
were analysed by SDS–PAGE. 
To test the binary Pol II–cMed interaction by protein pull-down, 3 µg purified 
Pol II was biotinylated on the Rpb3 subunit as described142 and immobilized on 20 µl 
Dynabeads M280 Streptavidin resin (Life Technologies), equilibrated in buffer R. 
1.5 µg cMed were incubated with immobilized Pol II or control beads for 1 h at 4 °C. 
Beads were washed four times and bound proteins were analysed by SDS–PAGE. To 
further assess the stability of Pol II–cMed by gel filtration, 80 µg Pol II were 
incubated with 1.5-fold less cMed as done for the cITC–cMed complex (see 
Preparation of cITC–cMed complex). Pol II–cMed complex was applied to size 
exclusion chromatography on a Superpose 6 10/600 GL equilibrated in buffer R, and 
peak fractions were analysed by SDS–PAGE. 
To test the interaction of Pol II with cMed variants comprising mutations in 
interface A, B and C, 2 µg recombinant cMed variant were incubated with 3 µg 
biotinylated Pol II immobilized on 15 µl Dynabeads M280 Streptavidin resin (Life 
Technologies) equilibrated in buffer R. Beads were washed four times and bound 
proteins were analysed by SDS–PAGE. cMed variants were purified according to the 
protocol for complete cMed, yet gave much lower yield. 
 
Protein crosslinking and mass spectrometry 
80 µg of purified cITC–cMed were crosslinked117 with 1–4 mM di-succinimidyl-
suberate (DSS-d0/d12, Creative Molecules Inc.) or 1–4 mM bis-sulfo-succinimidyl-
suberate (BS3-d0/d12, Creative Molecules Inc.) as described143. Crosslinked samples 
were digested with trypsin or AspN. Crosslinked peptides were enriched and analysed 
on a liquid chromatography system coupled to the electrospray ionization (ESI) 
source of an Orbitrap Elite mass spectrometer (Thermo Scientific)143. Crosslinks were 
identified by xQuest144 as described143. 35 µg of purified cMed were crosslinked with 
0.1–0.15 mM cyanurbiotin-dipropionyl succinimide (CBDPS-d0/d8, Creative 
Molecules Inc.) as described136. Crosslinked cMed was digested with trypsin and/or 
GluC, peptides were enriched and analysed on a liquid chromatography system 
coupled to the ESI source of an LTQ Orbitrap Velos mass spectrometer (Thermo 
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Scientific) as described140. Crosslinks were identified by DXMSMS Match of ICC-
CLASS136. 
 
Electron microscopy 
Purified cITC–cMed complex was crosslinked with 2 mM BS3 (Sigma) for 30 min at 
30 °C, and the reaction quenched with 50 mM ammonium bicarbonate. The 
crosslinked sample was purified by gel filtration using a Superose 6 10/600 GL 
equilibrated in buffer R. Fractions containing the complex were concentrated to 
~0.15 mg ml−1. Negatively stained samples of the cITC–cMed were prepared on 
continuous carbon coated grids (Quantifoil). Grids were glow-discharged 30 s before 
deposition of 4 µl sample (~0.15 mg ml−1) and incubated for 1 min. Grids were 
blotted between sequential transfers to two 40 µl drops distilled water, stained for 
1 min in a 40 µl drop 2% (w/v) uranyl acetate solution, and blotted until dry. To 
obtain an unbiased initial model, a 3D reconstruction was generated from particles 
selected from negative-stain tomography data. Single axis tilt series were recorded 
using Serial EM145 on a FEI Tecnai F20 microscope operated at 200 keV. Images 
were acquired from −54° to 54° with an angular increment of 3°. Images were 
recorded on a 4k×4k Gatan Ultrascan CCD camera with a defocus of –2 µm and at a 
nominal magnification of 68,000× (2.21 Å pixel−1). The cumulative dose per 
tomogram did not exceed 100 e– Å−2. To refine the negative-stain tomography 
reconstruction, a further 103 micrographs of the untitled sample were acquired with a 
range of defocus values (from –0.5 µm to –1.5 µm) and used for single-particle 
analysis. 
Cryo samples of the cITC–cMed were prepared on lacey carbon copper grids 
(Quantifoil). Grids were glow-discharged for 20 s before deposition of 4 µl sample 
(~0.15 mg ml−1) and incubated for 30 s. Grids were washed twice with 4 µl distilled 
water, blotted, and vitrified by plunging into liquid ethane with a manual plunger. 
Data was acquired using the TOM toolbox146 on a FEI Titan Krios operated in 
EFTEM mode at 300 keV. 2,972 movies were collected using a Gatan K2 Summit 
direct detector with a range of defocus values (from –1 µm to –2.5 µm) at a nominal 
magnification of 37,000× (1.35 Å pixel−1). The camera was operated in ‘super-
resolution’ mode (0.675 Å pixel−1) with exposure times of 0.2–0.3 s per frame, a dose 
rate of ~8 e– pixel−1 s−1, and a target total dose of 25–30 e– Å−2. Movies were binned 
once in Fourier space, and partitioned into 2,0482 quadrants that were aligned and 
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averaged using a CUDA implementation of a previously described algorithm147. The 
averaged 2,0482 images were used for image processing.  
 
Image processing 
Negative stain tomography data was processed using the TOM toolbox146. The tilt 
series was contrast-transfer function (CTF) corrected as described148. Due to the 
absence of colloidal markers, images were aligned using feature tracking before 
weighted back projection. 175 subvolumes were selected manually using EMAN2149 
and extracted with a 1603 voxel box size from the reconstructed tomogram. 
Reference-free alignment was performed in PyTom150. The obtained volume was used 
as the template for a 6D correlation search of the same tomogram151, yielding 675 
subvolumes. Subvolumes were aligned and averaged in PyTom to obtain a 3D 
reconstruction with an estimated resolution of 28 Å (Fourier shell correlation, 
FSC = 0.5) (Supplementary Fig. 4a). 
For negative-stain single-particle analysis, 21,365 particles were selected 
semi-automatically using e2boxer.py from EMAN2149. All 3D reconstructions were 
performed in RELION152. The unbiased negative-stain tomography reconstruction 
was low-pass filtered to 60 Å and used as an initial model for 3D reconstruction. The 
selected particles were extracted with a 1602 pixel box and pre-processed to normalize 
images and to remove pixel values more than 5 standard deviations from the mean 
value. Particle images were sorted by unsupervised 3D classification in RELION152 
into four classes with the regularization parameter T set to 1.5, an initial angular 
sampling interval of 7.5°, an offset search range of 5 pixels, and offset search steps of 
1 pixel (Supplementary Fig. 3a). This yielded one class of 8,815 particles that showed 
density for all components of the cITC–cMed. This class was refined using the 3D 
auto-refine procedure in RELION152 with default parameters, to an estimated 
resolution of 25.2 Å with the ‘gold-standard’ FSC = 0.143 (Supplementary Fig. 4c-e). 
For validation of the reconstruction quality, reference-free 2D class averages were 
calculated from all particles included in the final reconstruction using RELION152. 
The obtained averages were compared with SPIDER-generated153 forward projections 
of the final reconstruction (Supplementary Fig. 4b). 
For cryo-EM single-particle analysis, 89,769 particles were selected semi-
automatically using e2boxer.py from EMAN2149. CTF parameters were estimated 
using CTFFIND154. CTF correction and 3D reconstruction were performed in 
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RELION152. The selected particles were extracted with a 2802 pixel box and pre-
processed to normalize images and remove pixel values more than 5 standard 
deviations from the mean value. Sorting of particle images by unsupervised 3D 
classification led to three classes, Pol II–DNA/RNA (14,777 particles), cITC (4,439 
particles), and cITC–cMed (3,267 particles) (Supplementary Fig. 3b). Each class was 
refined only against the respective particles within this class using RELION152. All 
reference maps were filtered to 60 Å before refinement using the 3D auto-refine 
procedure in RELION152. Pol II–DNA/RNA and cITC classes were refined using a 
soft spherical reference mask (300 Å diameter), an initial angular sampling interval of 
7.5°, an offset search range of 3 pixels, and offset search steps of 1 pixel. Pol II–
DNA/RNA and cITC 3D reconstruction were refined to an estimated resolution of 
6.6 Å and 7.8 Å, respectively, at FSC = 0.143 (Supplementary Fig. 4h, m). For 
visualization and structural modelling of the EM densities, temperature factors of –
240 Å2 (Pol II–DNA/RNA) and –340 Å2 (cITC) were applied. The cITC–cMed class 
was refined using the 3D auto-refine procedure in RELION as Pol II–DNA/RNA and 
cITC, except with a soft SPIDER-generated153 reference mask in the shape of the 
cITC–cMed (maximum diameter of 360 Å) and an initial offset search range of 5 
pixels. The cITC–cMed 3D reconstruction was refined to an estimated resolution of 
9.7 Å at FSC = 0.143 (Supplementary Fig. 4r). For visualization and structural 
modelling of the cITC–cMed EM density, a temperature factor of –340 Å2 was 
applied. 
For validation of the reconstruction quality, reference-free 2D class averages 
were calculated from all particles included in the final reconstructions. The obtained 
averages were compared with SPIDER-generated153 forward projections of the final 
reconstructions (Supplementary Fig. 4f, k, p). To confirm the presence of only a 
single cITC–cMed conformation, we repeated 3D classification with rejected particles 
from class 1, 2, 5, 7, 8 of round 1 and cITC–cMed particles from class 4 of round 1 
(see 3D classification of cryo-EM data) with the Pol II–DNA/RNA reconstruction 
filtered to 60 Å resolution as initial model (Supplementary Fig. 3c, d). For these 3D 
classifications, an initial angular sampling of 7.5°, an offset search range of 5 pixels, 
and offset search steps of 1 pixel were employed. 
3D classification of cryo-EM data 
Unsupervised 3D classification of the cryo-EM data was performed using RELION152 
in a pseudo-hierarchical manner that consisted of seven rounds of classification 
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(Supplementary Fig. 3b). The obtained classes were iteratively reclassified and/or 
combined, based on the structures of Pol II155, human minimal pre-initiation 
complex39 and cITC–cMed. The regularization parameter T was set to 4 for all rounds 
of classification. The negative-stain single-particle reconstruction of the cITC–cMed 
complex was low-pass filtered to 60 Å as the initial model for round 1 of 3D 
classification. The cryo-EM reconstruction of the human minimal pre-initiation 
complex (EMD-2305) was low-pass filtered to 60 Å as the initial model for round 2b 
of 3D classification. All classification was performed with soft reference masks as 
detailed for 3D refinement of Pol II–DNA/RNA, cITC and cITC–cMed (see Image 
processing). 
Round 1 served to sort all 89,769 particles into eight classes to discard faulty 
particle images and identify a population of the complete cITC–cMed. The following 
initial sampling parameters were used: angular sampling of 7.5°, an offset search 
range of 15 pixels, and offset search steps of 3 pixels. Round 1 converged after 55 
iterations and gave rise to Class 3 (~13,400 particles, 14.8% of data) that showed 
strong density for the cITC and partial density for cMed. This class was submitted to 
a second round of classification (round 2a) into four classes with an initial angular 
sampling of 7.5°, an offset search range of 5 pixels, and offset search steps of 1 pixel. 
All following rounds of classification were performed using the same initial sampling 
parameters used for round 2a. Class 3 of round 2a (3,267 particles, 3.7%) revealed the 
cITC–cMed complex with equal intensity of cITC and cMed, and was consequently 
refined as detailed (see Image processing). To explore any remaining heterogeneity, 
class 3 of round 2a was sorted into four classes (round 3a). This yielded class 1 and 2, 
lacking density for either upstream DNA–TFIIF–TFIIB–TBP or upstream DNA–
TFIIB–TBP and the mobile plank of cMed (Supplementary Fig. 3b), and class 3 and 4 
that varied appreciably in the mobile plank domain (Fig. 24d). Due to the small 
number of particle images, classes from round 3a were not refined. 
Class 3 and 6 of round 1 showed density for Pol II and were consequently 
combined (~50,000 particles, 55.5%) and classified into eight classes (round 2b). This 
yielded class 2 (~14,000 particles, 15.5%) that presented a cITC with weak density 
for general transcription factors and upstream DNA. Class 2 of round 2b was 
therefore further classified into three classes (round 3b) that resulted in the cITC 
containing class 2 (~3,700 particles, 4.1%). To obtain a larger set of homogenous 
cITC particles, class 1 of round 2a and class 2 of round 3b were combined (~7,300 
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particles, 8.1%) and sorted into four classes (round 4b). This led to class 2 of round 4b 
(4,439 particles, 4.9%) that revealed the complete cITC. The complete cITC was 
subsequently refined as detailed (see Image processing). 
Class 1 and 8 of round 2b and class 3 of round 3b displayed density only for 
Pol II–DNA/RNA and were consequently combined (~25,000 particles, 27.7%) and 
further sorted into four classes (round 5). The resulting class 3 (14,777 particles, 
16.4%) showed density for the Pol II–DNA/RNA complex with weak density for the 
Rpb4–Rpb7 subcomplex and was subsequently refined as detailed (see Image 
processing). Class 1 of round 5 (~3,200 particles, 3.5%) presented density for 12-
subunit Pol II–DNA/RNA, but was not refined due to the small number of particles 
and poor orientational distribution (Supplementary Fig. 3b). Class 4 of round 2a and 
class 1 of round 3b displayed density for the binary Pol II–TFIIF–DNA/RNA 
complex and were combined (~12,900 particles, 15%, round 6). This complex 
presented with identical features found in the cITC and was not analysed further 
(Supplementary Fig. 3b). 
 
Local resolution, filtering and variance estimation 
Local resolution maps (LRMs) were obtained using a method156 implemented to run 
on a Graphics Processing Unit. A sliding window of 403 voxels was centred around 
each voxel, extending the original half-maps through mirroring at the borders. The 
FSC at 0.143 was then calculated within the window and assigned to the central 
voxel. Given the low particle counts involved in the reconstructions and the resultant 
non-uniform sampling, five differently randomized pairs of half-maps generated in 
RELION152 were processed independently and the results averaged to obtain a more 
robust estimate. Nevertheless, the maximal value for the local resolution was capped 
at the global FSC = 0.143 value to prevent enhancing of noise. Therefore, even 
though some regions, notably the Pol II density, clearly exhibited higher resolution 
than the nominal, LRMs were used only to limit the resolution locally, for a 
conservative interpretation of our data. 
To perform local filtering, maps were downscaled for the Nyquist frequency 
to match the highest frequency value within the respective LRM. Look-up maps were 
then created by low-pass filtering the original map to each integer frequency value 
present in the LRM. For each voxel, a value linearly interpolated between the two 
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look-up maps closest to its non-integer frequency was copied to the output. Finally, 
the locally filtered maps were rescaled to their original size. 
Variance maps were generated for each cryo-EM reconstruction as an 
additional metric for assessing reconstruction quality and structural variability. These 
were obtained by implementing a described bootstrap approach157, using the direct 
Fourier inversion method158 for the reconstructions. As RELION’s data processing 
pipeline could not be used for this task, the aligned micrographs were CTF-corrected 
by means of automatic defocus determination and phase flipping in the TOM 
toolbox146. Single particle views were then extracted using RELION’s position and 
rotation estimates. Differently sampled 12.5% fractions of the entire particle set were 
used to create 4,000 reconstructions. The variance between these reconstructions was 
calculated for each voxel position and normalized by the respective intensity value 
(Supplementary Fig. 4j, o, t). 
 
Structural modelling 
To generate unbiased models, known structures or homology models were 
sequentially rigid-body fitted using an automated global 6D correlation search in 
Situs159 (Figs 19a and 21a). As the majority of fitted models account for only a small 
fraction of the density, a Laplacian filter was applied for fitting (except for fitting the 
10-subunit Pol II structure into the Pol II–DNA/RNA and cITC maps, and for fitting 
the cITC model lacking Rpb4–Rpb7 into the cITC–cMed map). After fitting of each 
component, difference maps were generated using UCSF Chimera160 to reduce the 
search space in subsequent searches. 
For the cITC model, we automatically fitted crystal structures of Pol II 16,161, 
TFIIB residues 22–21316, TBP29, and homology models of TFIIF40, and the TFIIB C-
terminal cyclin domain40 (Fig. 19a). Pol II, DNA, and the Tfg1 charged helix were 
slightly adjusted manually using COOT124 to accurately reflect the density. The 
crystal structure of the initially transcribing complex27 (PDB code 4A3D) was used 
for fitting of Pol II–DNA/RNA and initial fitting of cITC, as it presents the most 
complete model of Pol II except for the protrusion domain. For the Pol II–DNA/RNA 
model Rpb4–Rpb7 was excluded, due to the weak density in this region. For fitting of 
the 10-subunit Pol II–TFIIB model, we combined structures of initially transcribing 
Pol II (PDB code 4A3D, excluding Rpb4–Rpb7) and initially transcribing Pol II–
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TFIIB complex (PDB code 4BBS, chain M, TFIIB residues 22–118). After visual 
inspection of the cITC density, the nucleic acids and Pol II domains clamp core, wall 
and protrusion in the initially transcribing Pol II structure (PDB code 4A3D) were 
replaced with the corresponding regions from the initially transcribing Pol II–TFIIB 
complex structure (PDB code 4BBS). For fitting of Rpb4–Rpb7, chains D and G from 
the initially transcribing Pol II structure (PDB code 4A3D) were used. 
For fitting the structure of the TFIIB N-terminal cyclin domain–TBP–DNA 
complex, the atomic coordinates of the equivalent Homo sapiens complex (PDB code 
1VOL) were used as a template. TBP and the TFIIB N-terminal cyclin of 1VOL were 
replaced with S. cerevisiae TBP (PDB code 1YTB, chain A) and the S. cerevisiae 
TFIIB N-terminal cyclin (PDB code 4BBS, chain M and residues 122–213), 
respectively. The model of the TFIIF dimerization domain was generated as 
described40, containing S. mikatae Tfg1 residues 92–143 and 343–412, and S. 
cerevisiae Tfg2 residues 54–138 and 208–227. The homology model of the TFIIB C-
terminal cyclin (residues 233–342) was based on the H. sapiens TFIIB C-terminal 
cyclin (PDB code 1VOL). The Tfg1 charged helix was placed manually using 
COOT124 according to the chemical environment. Further density in shape of duplex 
DNA was observed upstream and downstream of TATA-box DNA, and downstream 
of the active site. This density was modelled with canonical duplex B-DNA, 
generated in COOT124. NAMD162 was used to optimize DNA geometry using the 
CHARMM force field163. The DNA sequence of all nucleic acid models was edited in 
COOT124 to match the sequence of the employed nucleic acid scaffold. 
The cITC–cMed model was generated by sequential fitting of cITC lacking 
Rpb4–Rpb7, and the three regions of an improved S. cerevisiae Mediator head 
module model (Fig. 21a). The construction of an improved head module was required 
because the published structures are at 4.3 Å resolution and contain out-of-register 
errors and are lacking several regions99,164. To account for the known flexibility 
within the head module139, its regions neck (including joint), movable jaw, and fixed 
jaw were fitted independently. To model the fixed jaw tooth and the nose domains, 
we used the structure of S. cerevisiae Med17C–Med11C–Med22C (PDB code 
4H62139). For the movable jaw, the structure of S. cerevisiae Med8C–Med18–Med20 
(PDB code 2HZS70) was completed with Med18 residues 69-93 from the structure of 
S. cerevisiae Med18–Med20 (PDB code 2HZM, chain D) to account for additional 
residues visible in the electron density. The shoulder domain was modelled with 
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MODELLER135 based on its S. pombe counterpart (PDB code 4H61139). For the arm, 
finger, spine and joint domains of the head module, our S. pombe head module (PDB 
code 4H63139) was used as a model. Med11 and Med22 helices α1 and α2 were 
replaced with the corresponding helices from the S. cerevisiae Med11N–Med22N 
structure (PDB code 3R84). Other S. pombe residues were replaced with their S. 
cerevisiae counterparts, based on sequence alignments. The obtained models for all 
head module domains except the finger were individually fitted onto the 
corresponding elements in the published structure of the S. cerevisiae head module 
(PDB code 4GWP), using secondary structure matching in COOT124. A 2Fo-Fc 
electron density map corresponding to the published S. cerevisiae head module 
structure was calculated. The map was used to fit our model of the finger element and 
to adjust the rest of our model when required. The linker between helices α4 and α5 
in Med8 and the Sc specific helix between strand β1 and helix α3 were built 
manually. The geometry of the obtained head module model was regularized in 
COOT124 and with PHENIX123. All figures and movies were generated using UCSF 
Chimera160 and PyMol. 
 
Immobilized template assay 
The immobilized template assay was performed essentially as described100 using 
nuclear extract from srb4-ts54 or wild-type (BY4741) S. cerevisiae strains and a linear 
HIS4 promoter19,100. The srb4-ts extract was complemented with recombinant head 
module (4.5 pmol) as indicated in Fig. 25b. Samples were applied to SDS–PAGE, 
transferred onto a polyvinylidene difluoride membrane (Millipore) and probed by 
antibodies anti-Rpb3 (1Y26, NeoClone, dilution 1:1000), anti-TFIIB (ab63909, 
Abcam, dilution 1:4000), anti-TBP (sc-33736, Santa Cruz, dilution 1:400), anti-
Med17 (1:10000 dilution), kindly provided by Steven Hahn (Fred Hutchinson Cancer 
Research Center), anti-Flag-tag (F1804, Sigma, 1:1000 dilution), and anti-Med2 (sc-
28058, Santa Cruz, 1:1000 dilution). Secondary antibodies anti-rat IgG HRP (A9037, 
Sigma, dilution 1:3000), anti-mouse IgG HRP (170-6516, Bio-Rad, dilution 1:3000), 
anti-rabbit IgG HRP (sc-2004, Santa Cruz, dilution 1:3000) and anti-goat IgG HRP 
(sc-2020, Santa Cruz, dilution 1:3000) were used. Antibody detection was achieved 
with Pierce enhanced chemiluminescence (ECL) western blotting substrate (Thermo 
Scientific) and Amersham Hyperfilm ECL (GE Healthcare). 
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Comparative Dynamic Transcriptome Analysis (cDTA) 
cDTA enables global analysis of newly synthesized RNA165 that reveals defects in 
transcription with much higher sensitivity than conventional steady-state methods. 
cDTA was carried out as described165 using the S. cerevisiae heterozygous 
Med17/med17Δ strain (Euroscarf) transfected with plasmids pRS315-SRB4139 or 
pRS315-srb4-ts139, and Y40343-wildtype (Euroscarf) or Med18-FRB-KanMX6 
(Euroscarf) strains. Heat shock of SRB4 and srb4-ts strains was applied for 18 or 
60 min at 37 °C before RNA labelling as described165. To deplete the Med18 subunit 
from the nucleus, anchor-away experiments were performed by rapamycin treatment 
(1 µg ml−1 in 200 ml YPD) for 18 or 60 min at 30 °C before RNA labelling166. Data 
analysis was as described165. 
 
CTD phosphorylation assay 
Endogenous TFIIH was purified as described17. Purified Pol II (2.5 pmol), 7-subunit 
head module (1.25 pmol), 6-subunit middle module (1.25 pmol), cMed (2.5 pmol) 
were added as indicated in Fig. 27f and incubated on ice for 10 min before addition of 
TFIIH (~0.02 pmol) and 300 µM ATP. Reactions were incubated for 25 min at 25 °C, 
applied to SDS–PAGE, transferred to a nitrocellulose membrane (GE Healthcare) and 
probed with primary antibodies anti-Ser5-P (3E10, dilution 1:20), provided by D. 
Eick (Helmholtz-Zentrum München), and anti-Rpb3 (1Y26, NeoClone, dilution 
1:2,000). Secondary antibodies anti-rat IgG HRP (A9037, Sigma, dilution 1:3,000) 
and anti-mouse IgG HRP (170-6516, Bio-Rad, dilution 1:3,000) were used. Antibody 
detection was achieved with Pierce enhanced chemiluminescence (ECL) western 
blotting substrate (Thermo Scientific) and an Advanced Fluorescence Imager (Intas).
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3 Results and Discussion 
3.1 Structure of the Mediator head module 
The work presented in this chapter was published. 
 
L. Larivière*, C. Plaschka*, M. Seizl, L. Wenzeck, F. Kurth, P. Cramer. Structure of 
the Mediator head module. Nature (2012) 492, 448–451.  
*These authors contributed equally. 
3.1.1 Structures of Med6 and Med17C–Med11C–Med22C 	  
 
Figure 4 | Structures of Med6 and Med17C–Med11C–Med22C. a, Ribbon model of the Sp 
Med6 crystal structure. b, Conserved surface groove in Med6. Residues that are invariant or 
conserved among seven yeast species are in green or yellow, respectively (Supplementary 
Fig. 1). c, Ribbon model of the Sc subcomplex Med17C–Med11C–Med22C crystal structure. 
‘Tooth’ and ‘nose’ domains are indicated. Dashed lines indicate disordered regions. 
 
Extending structural analysis of Mediator21, we determined the crystal structure of a 
bacterially expressed Med6 variant (Sp residues 9–180) at 2.7 Å resolution (Fig. 4a, 
Supplementary Fig. 1, and Supplementary Table 1). The structure revealed a core 
domain with a five-stranded antiparallel β-sheet, two pairs of α-helices flanking a 
conserved groove, and a flexible C-terminal helix α5 (Fig. 4a, b). Bacterial expression 
also provided the head subcomplex Med17C–Med11C–Med22C, which consists of C-
terminal regions in Med17, Med11 and Med22 (ref.100) and constitutes the fixed jaw99 
(see 2.2.3 and Fig. 4b). The crystal structure at 3.0 Å resolution (Supplementary Table 
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1) revealed two subdomains we call ‘tooth’ and ‘nose’ (Fig. 4c). The tooth contains 
Med11C, Med22C and Med17C residues 383–541 and 594–611. It forms a five-
stranded β-sheet that is flanked by five helices, three from Med17C and one each 
from Med11C and Med22C. The nose comprises Med17C residues 542–580 and 612–
687 and forms another five-stranded β-sheet with two flanking helices. 
 
Figure 5 | Bacterial expression vectors. Schematic representation of the plasmids used in 
this study for the expression of the a, crystallization construct of Sp Med6. The variant lacks 
only the non-essential terminal tails. b, Sc Med17C/Med11C/Med22C subcomplex. Two 
plasmids were used for co-expression, one expressing Med17C, the other expressing a 
Med11C-Med22C fusion polypeptide (see Supplementary Methods). c, full length Sc head 
module. Co-expression was driven from a single plasmid with three T7 promoters, one for 
Med17 expression, one for tricistronic expression of Med22, Med11, and Med6, and one for 
tricistronic expression of Med8, Med18, and Med20. d, full length Sp head module. Three 
plasmids were used for co-expression, each harboring a single T7 promoter, one expressing 
Med6, one expressing Med8, Med18, and Med20, and one expressing Med17, Med22, and 
Med11. e, Sp head variant used for crystallization. RBS, ribosome binding site; His tag, 
6xHistidine tag; ori, origin of replication; lacI, gene encoding Lac repressor. Sm, Amp and Kan 
refer to streptomycin, ampicillin and kanamycin resistance genes, respectively. 
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3.1.2  Expression, crystallization and structure solution of the Sp 
Mediator head module 
We prepared the entire Sc head module by co-expressing its seven subunits in 
Escherichia coli (see 2.2.3 and Fig. 5c). The purified module (Fig. 6a) supported 
activator- and promoter-dependent transcription from three different promoters in 
vitro (Fig. 6b). Crystals of the Sc head module were obtained in 2007, but persistently 
diffracted to low resolution. We therefore prepared the head module from Sp (Fig. 
5d). The purified module (Fig. 6a) did not crystallize, but crystals were obtained for a 
variant lacking three non-essential parts, Med6 residues 181–216, Med17 residues 1–
76 and Med20 (Fig. 5e and 6a). 	  
 
Figure 6 | Structure of Sp Mediator head module. a, SDS–polyacrylamide gel 
electrophoresis (PAGE) analysis of purified recombinant head modules of Sc (left), full-length 
Sp (middle) and the crystallized Sp variant (right). b, Recombinant Sc head module supports 
Results and Discussion 
 46 
in vitro transcription from three different promoter types. Activity of nuclear extracts from 
SRB4 and srb4-138 (srb4ts) strains was assessed on promoters HIS4, TMT1 and ACT1. Pol 
II-dependency was confirmed by a-amanitin sensitivity (0.04 mM, lane 3). Addition of 5 pmol 
recombinant Sc head module (lane 5) to inactive srb4ts extracts (lane 4) restored activity. c, 
Two views of a ribbon representation of Sp Mediator head module structure. Subunits are in 
different colours. Subunit Med20 is not present in the crystals but was unambiguously 
modelled and positioned by superimposing the previous Sc Med18–Med20 heterodimer 
structure70. 
 
We determined the Sp head module structure de novo by multiple 
isomorphous replacement with anomalous scattering (see 2.2.3 and Fig. 8a). 
Modelling required selenomethionine sequence markers (Fig. 7b) and the four 
available structures of subcomplexes (Fig. 4, ref70,100). Diffraction data to 3.4 Å 
resolution (Table 13) resulted in excellent electron density (Fig. 7c, d) and a refined 
structure that has a free R factor (Rfree) of 25.8% (Table 13) and contains 87% of the 
residues in the variant.  
 
Table 13 | Data collection and refinement statistics for Sp head module crystals. 
 Native Ta6Br14 Yb-DTPA-BMA SeMet 
Data collection     
Space group P3221 P3221 P3221 P3221 
Cell dimensions       
    a, b, c (Å) 145.6, 145.6, 
241.6 
145.4, 145.4, 
233.2 
146.0, 146.0, 
232.6 
146.0, 146.0, 
238.6 
Wavelength (Å) 0.99977 1.25537 1.38633 0.97940 
Resolution (Å)† 3.4 (3.49-3.40)* 4.7 (4.82-4.70) 4.0 (4.1-4.0) 3.8 (3.9-3.8) 
CC1/2‡ 99.9 (24.0) 99.9 (13.8) 99.7 (23.0) 99.6 (22.1) 
Completeness (%) 100.0 (99.9) 99.9 (99.9) 99.7 (97.2) 99.9 (99.2) 
Redundancy 10.0 (9.2) 4.6 (4.7) 5.2 (5.2) 5.2 (4.7) 
Rmerge (%) 12.5 (412.4) 9.1 (474.1) 20.4 (860.3) 18.1 (246.5) 
I/σI 15.2 (0.6) 8.4 (0.4) 7.6 (0.3) 8.9 (0.6) 
     
Refinement     
Resolution (Å) 126–3.4    
No. reflections 41,454    
Rwork/Rfree 23.2/25.8    
No. atoms     
    Protein 9254    
    Ligand     
B-factors     
    Protein 166    
    Ligand     
R.m.s deviations     
    Bond lengths (Å)  0.009    
    Bond angles (°) 1.13    
*Highest resolution shell is shown in parenthesis. 
†Resolution limits are provided using the CC1/2 > 10% criterion167. Using the traditional criterion of I/σI 
> 2.0, the resolution limit of the native crystal is 3.7 Å. 
‡CC1/2 = percentage of correlation between intensities from random half-datasets167. 
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Figure 7 | Electron density maps for the Sp Mediator head module. a, Initial unbiased 
MIRAS electron density map (cyan, contour level 1σ) with the final structure superimposed 
(blue coils, right side view). b, Anomalous difference Fourier map for selenomethionine-
containing head module (magenta, contour level 2.5σ) with an outline of the structure 
superimposed (blue ribbon, right side view). Sulphur atoms of methionine residues are shown 
as green spheres. c, mFo–DFc simulated annealing omit maps (cyan, contour level 3s) with 
the final model superimposed, shown as sticks with carbon atoms coloured by subunit (see 
Fig. 6). Shown are three regions of the head module, Med17 helix α3 (left), a part of the nose 
(middle), and a part of Med6 (right). Med17 residues 186 to 204, Med17 residues 515 to 533, 
and Med6 residues 78 to 92 were omitted in the map calculation, respectively. d, mFo–DFc 
simulated annealing omit maps (cyan, contour level 3σ) for Med11 and Med22 linker regions 
(left and middle, respectively) and the Med17 b-sheet from the ‘joint’ (right). The final model is 
superimposed, shown as ribbons and coloured according to subunits (see Fig. 6). Med17 
helix a4 was omitted for clarity. 	  
3.1.3  Structure of Sp Mediator head module 
The Sp head module structure reveals an asymmetric multiprotein assembly that 
resembles the head of a crocodile with one limb (Figs 6c and 8a). The structure 
reveals all folds and previously unobserved regions, and is partitioned into eight 
elements (Fig. 8a, b). The neck submodule is formed by Med6, Med8 and parts of 
Med11, Med17 and Med22, and consists of ‘spine’, ‘shoulder’, ‘arm’ and ‘finger’ 
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elements (Figs 8a, b and 9). The spine comprises seven helices, six forming a long 
bundle (Med8 α5, Med17 α3, Med11N–Med22N (ref.100), and a seventh 
perpendicular helix (Med8 α4). The arm consists of a short four-helix bundle (Med6 
α5, Med8 α1/2, Med17 α1), two pairs of helices (Med17 η1/α2, Med8 α2′/α3), and a 
two-stranded sheet (Med8 β1, Med17 β1). The arm binds the shoulder, which consists 
of the Med6 core (Fig. 4a). The finger is an exposed C-terminal β-hairpin in Med6 
(Fig. 8a, d). The fixed and moveable jaws consist of subcomplexes Med17C–
Med11C–Med22C (Figs 4c and 8a) and Med8C–Med18–Med20 (ref.70), respectively. 
Both jaws are connected to the spine. The fixed jaw is connected via the 
‘joint’ that contains a four-stranded β-sheet formed by Med17 residues 215–259, and 
short linkers in Med11 and Med22. The joint may change its structure as it contains 
many conserved glycine and serine residues. Deletion of the Med17 part of the joint 
did not cause lethality in yeast, but essentially abolished activated transcription in 
vitro (Fig. 10a, b). The moveable jaw binds the spine via Med8C, a helix extending 
from the Med18–Med20 heterodimer98 (Fig. 8a, d), and also contacts the joint and 
tooth.  
Conservation of the module surface is highest at the shoulder and arm (Fig. 
8c), probably because this region binds the middle module96,101. Deletion of the 
shoulder caused synthetic lethality (Fig. 10). 	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Figure 8 | Structural elements and surface conservation. a, Eight structural elements in 
the Mediator head module. Ribbon model of the Sp head module structure is coloured 
accordingly (see Fig. 9). b, The structure resembles the head of a crocodile with one limb. 
The eight structural elements received corresponding names, and previously introduced 
names for the three submodules neck, fixed jaw and moveable jaw are preserved. c, Surface 
conservation of the Sp Mediator head module. Residues that are invariant or conserved 
among seven yeast species (Supplementary Fig. 1) are in green or yellow, respectively. d, 
Ribbon representation of the five non-globular head subunits (top view) coloured according to 
structural elements as in a (see Fig. 9). 
 
 
	  
Figure 9 | Subunit structure within the Sp Mediator head module. The head module and 
its individual subunits are represented as ribbons (right side view), coloured by subunit (left) 
or according to structural elements (right). 
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Figure 10 | Structural element deletions affect Mediator head function in vivo and in 
vitro. a, Yeast complementation assays were performed with wild-type MED17, an empty 
vector, or MED17 lacking the joint (Δjoint, Δ321-369) (see 2.2.3). b, In vitro transcription was 
performed with extract from the srb4-138 (srb4ts) strain in the absence of recombinant head 
module (rHead; lanes 1-2), in the presence of 5 pmol wild-type rHead (lanes 3-5), or 5 pmol 
rHead Δjoint (lanes 6-8) as described (see 2.2.3). c, Yeast complementation assays were 
performed with wild-type MED6, an empty vector, a MED6 variant corresponding to the 
construct used for the Sp head module crystallization (residues 1- 225), or MED6 lacking the 
shoulder (Δshoulder, residues 163-295) as described (see 2.2.3). 
 
3.1.4  Revised Sc Mediator head module backbone model 
We prepared a homology model for the Sc head module based on our structures of the 
Sp module and the Sc subcomplexes Med17C–Med11C–Med22C, Med11N–Med22N 
(ref.100) and Med8C–Med18–Med20 (ref.70). After minor adjustments, the model 
explained the published electron density and selenium positions99. Compared with the 
published model99, four α-helices were swapped, a β-sheet was added in the tooth, 
and the amino acid register was adjusted for 46% of the residues outside the moveable 
jaw. Thus the structures of the Sp and Sc head modules are well conserved although 
the structured regions show only 15% sequence identity (Supplementary Fig. 1). Sc-
specific differences are found in six helices; three are shorter (Med8 αC, Med17 α5, 
Med22 α1), one is longer (Med11 α1) and two are rotated (Med17 α7, Med22 α3). 
Because of poor electron density99, the revised Sc model lacks the joint, part of the 
arm, the sheet in the shoulder, the finger and five protein linkers. 
3.1.5  Structural comparisons reveal head module flexibility 
Structural comparisons reveal flexibility within the head module. The position of the 
shoulder changes in different Sp module crystals (Fig. 11a), owing to a flexible 
connection to Med6 helix α5. The finger is mobile in the free Med6 structure. 
Flexibility of the moveable jaw is indicated by high B-factors (Fig. 11b) and electron 
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microscopic results71. Movement of the nose with respect to the tooth is revealed by 
comparison of the Sc model with the free fixed jaw structure (Fig. 11c). Comparison 
of the Sp structure with the Sc model indicates that the neck can rotate with respect to 
the jaws (Fig. 11e). The rotation may be accommodated by the joint, which uses 
conserved hydrophobic residues to anchor the tooth to the spine. Thus the head 
module contains at least four mobile peripheral elements, the shoulder, finger, 
moveable jaw and nose. 
 
Figure 11 | Structural comparisons reveal head module flexibility. a, The shoulder 
adopts different orientations relative to the arm in different Sp head module crystals. b, B-
factor distribution within the refined Sp head module structure reveals a high degree of 
flexibility of the moveable jaw. c, Comparison of the orientation of the nose relative to the 
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tooth between the new Sc head module backbone model and the free Sc 
Med17C/Med11C/Med22C structure. Tooth elements are superimposed. d, Comparison of 
the orientation of the nose relative to the tooth between the new Sc head module backbone 
model and the Sp head module structure. Tooth elements are superimposed. e, 
Superposition of Sc and Sp tooth elements reveals a different orientation of the spine relative 
to the jaws. Arm, shoulder and finger elements were omitted for clarity. 
 
3.1.6  Head module integrity and interactions 
	  
Figure 12 | Head module integrity and interactions. a, Location of sites of Sc mutations 
that may influence module stability. Mutations were mapped onto the Sp head module 
structure using alignments shown in Supplementary Fig. 1. Cα atoms of mutated residues are 
shown as spheres. Mutations that may affect intrasubunit stability, intersubunit stability or with 
uncertain affects are in yellow, dark red or cyan, respectively. b, Location of sites of Sc 
mutations that may influence interactions with the Pol II core, CTD and TFIIH. Mutations were 
mapped on the Sp head module using alignments shown in Supplementary Fig. 1, with Cα 
atoms represented as spheres. Mutations that suppress CTD truncation phenotypes, interact 
genetically with Rpb3 mutations or lead to a loss of interaction with TFIIH are shown as 
orange, magenta or blue spheres, respectively. A Med11 mutation in the spine, Thr31Ala, 
leads to reduced interaction with TFIIH20. 	  
To determine the phenotypes of known mutations, we mapped 47 sites of 55 Sc head 
module mutations onto the Sp structure (Fig. 12, Supplementary Fig. 1). Most 
temperature-sensitive mutations map to protein cores or domain interfaces and 
apparently influence module stability (Fig. 12a). These include mutant srb4-138 that 
contains six Med17 mutations required for temperature sensitivity54, including 
mutations Ser226Pro and Phe649Ser that apparently destabilize the arm and nose, 
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respectively. The human MED17 mutation Leu371Pro (residues 504 and 389 in Sc 
and Sp, respectively) is associated with infantile cerebral and cerebellar atrophy168 
and perturbs MED17 helix α5 in the tooth. The temperature-sensitive phenotype for 
Med11 mutations Glu17Lys/Leu24Lys (ref.100), Leu66Pro (refs20,100), and Glu92Ser 
(refs20,100) is also explained by fold destabilizations. The mutation med6-ts1 and 
mutations in the med6-ts6 allele169 may destabilize the shoulder. Mutant med6-ts2 
contains six point mutations169, of which Gln49Leu changes the conserved surface 
implicated in binding other Mediator parts, Phe125Tyr changes the shoulder–arm 
interface, and Phe194Leu may destabilize the finger–spine interface. 
The structure also explains how mutant phenotypes are suppressed by 
secondary mutations. The SRB4-101 mutation Glu286Lys rescues the med6-ts2 
phenotype169, apparently by creating a new salt bridge between Med17 helix α3 and 
Med6 helix α5. The MED6-101 mutation170 may suppress the srb4-138 phenotype 
because mutation Asp152Tyr between the shoulder and arm compensates for 
decreased stability of the neck. The SRB6-201 (ref.170) mutation Asn59His may also 
suppress the srb4-138 phenotype by stabilizing the neck. 
Other genetic data implicate the fixed jaw in interactions with Pol II (Fig. 12b, 
Supplementary Fig. 1 and Supplementary Table 2). The head module interacts with 
Pol II near subunit Rpb3, and this contact is required for regulated transcription171,172. 
Mutations causing co-lethality with the Rpb3 mutation rpb3-2 map to the fixed jaw 
(Fig. 12b). Mutants med17-208 and med17-257 both contain the mutation Glu669Asp 
that is located on the nose surface and may abolish the head–polymerase interaction 
that is weakened by Rpb3 mutation. Mutant med17-sup1 rescues the phenotype of 
Rpb3 mutation Ala159Gly (ref.171) and contains two mutations in the fixed jaw (Fig. 
12b). Consistent with an interaction between the head module and the Pol II region 
around Rpb3, a mutation in the adjacent polymerase dock domain has a cold-sensitive 
phenotype that is rescued by SRB mutations48 in the joint and moveable jaw (rpb1-
14). Mutants med17-68, med17-158 and med17-327 all contain mutations that are 
predicted to destabilize the fixed jaw. 
Mediator also interacts with the carboxy-terminal domain (CTD)173,174 that 
extends from the polymerase core near the dock domain. CTD truncation causes a 
cold-sensitive phenotype that is rescued by mutations44,47,48 that map mainly to the 
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joint (Fig. 12). The mutation SRB4-1 maps to the joint–tooth interface, whereas the 
mutation SRB6-1 may stabilize the spine and adjacent joint. The mutation SRB5-1 in 
Med18 helix α1 may strengthen joint interaction with the moveable jaw, whereas 
mutation SRB2-1 alters the moveable jaw surface. These results suggest that the joint 
and moveable jaw are involved in CTD binding and/or that they are required for 
structural changes in Mediator that enable CTD binding. However, other Mediator 
regions probably contribute to interactions with the CTD because the head module is 
insufficient for CTD binding in vitro97. The flexibility and extended shape of the head 
module, which is 170 Å long, 95 Å high and 65 Å wide, may allow for several 
interactions not only with Pol II but also with transcription factors TFIIB52,95, 
TFIIH20,100 and the TATA box-binding protein70,71. 
3.2 Model of the Mediator middle module based on protein 
cross-linking 
The work presented in this chapter was published. 
 
L. Larivière, C. Plaschka, M. Seizl, E. V. Petrotchenko, L. Wenzeck, C. H. Borchers, 
P. Cramer. Model of the Mediator middle module based on protein cross-linking. 
Nucleic Acids Research (2013) 41, 9266–9273. 	  
The essential core of Mediator consists of two conserved modules, the head and 
middle modules. Whereas the structure of the head module is known, the structure of 
the middle module is lacking. We therefore determined a model of the middle module 
based on protein cross-linking. Recombinant middle module was obtained by co-
expression of its six subunits, Med4, Med7, Med9, Med10, Med21, and Med31 from 
a single plasmid (Fig 13a).  
50 µg of middle module were incubated with isotope-labeled CBDPS175. 
CBDPS reacts with primary amines in lysine side chains and protein N-termini, and 
harbors a biotin moiety. Cross-linking efficiency was monitored by SDS-PAGE (Fig 
13b). After protease digestion, cross-linked peptides were enriched by affinity 
chromatography using avidin. Peptides and their fragments were detected with high-
resolution LC-MS (see 2.2.4). Measurements and subsequent analysis resulted in 55 
mass spectra that matched cross-linked peptides140. An example is shown in Fig. 13c. 
These spectra correspond to 40 unique linkage pairs, among which 19 and 21 were 
intra- and inter-subunit cross-link pairs, respectively (Fig 14).  
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Eight cross-link pairs could be mapped on the two known crystal structures of 
middle module subcomplexes, seven on the Med7C/Med21 subcomplex, and one on 
the Med7N/Med31 subcomplex (Figs 14 and 15). The mapped cross-link pairs fell 
within the distance cut-off between Cα atoms of 26 Å. 
 
 
Figure 13 | Preparation and CX-MS analysis of the Mediator middle module. a, 
Schematic representation of the plasmid used for Mediator middle module recombinant 
expression. Coding sequences are colored according to a code used throughout (Med4, 
cyan; Med7, orange; Med9, brown; Med10, slate; Med21, magenta; Med31, green). Co-
expression was driven from a single plasmid with two T7 promoters, one for bicistronic 
expression of Med9 and Med4, and one for tetracistronic expression of Med31, Med10, Med7 
and Med21. His tag, deca-histidine tag; ori, origin of replication; lacI, gene encoding Lac 
repressor; RBS, ribosome binding site; Sm, streptomycin resistance gene. b, SDS-PAGE 
analysis of the middle module cross-linked with different concentrations of CBDPS. c, 
Fragmentation spectrum of a cross-linked peptide. 
 
 
 
Figure 14 | Map of lysine-lysine cross-link pairs of the Mediator middle module. The 
primary structure of the six subunits is drawn schematically to scale. α-helices from crystal 
structures or from predictions are indicated as cylinders and colored as in Fig. 13. α-helices 
for which crystal structures are available or which could be modeled are labeled. White boxes 
enclose regions that could be modeled. Hatched boxes indicate regions that are dispensable 
for module assembly. Black and green dashed lines indicate cross-links that could be 
mapped onto the middle module model or not, respectively. 
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3.2.1 Model of the Med4/Med9 dimer 
The structure of the Med4/Med9 heterodimer is unknown. Secondary structure 
prediction suggests that Med4/Med9 shares a common 4-helix bundle fold with head 
module subunits Med11/Med22100 and middle module subunits Med7/Med21101.  
Based on this we generated a homology model of the Med4/Med9 heterodimer (Fig. 
15) that explained all seven cross-links observed within the Med4/Med9 heterodimer 
(3 intra-subunit cross-links, 4 inter-subunit cross-links, Figs 14 and 15). The model 
was further supported by the resulting location of hydrophobic residues, which form 
the interface between the two subunits. 
3.2.2 Model of the Med4/Med9-Med7/Med21 tetramer 
To position the Med4/Med9 model relative to the Med7C/Med21 heterodimer crystal 
structure, we assumed that the two heterodimers interact as observed for symmetry-
related Med7C/Med21 heterodimers in the Med7C/Med21 crystal structure101. In both 
crystal forms of Med7C/Med21, heterodimers pack against each other via the 
conserved ends of their protruding coiled-coils101. The resulting Med4/Med9–
Med7C/Med21 model is strongly supported by four cross-links observed between the 
two heterodimers (Figs 14 and 15). The model is further supported by a clustering of 
hydrophobic residues in the heterodimer-heterodimer interface. 
3.2.3 Positioning of Med10 and Med31 
Tertiary structure prediction of the Med10 subunit using HHpred138 suggests that 
Med10 is homologous to the N-terminal region of the head module subunit Med8, for 
which the structure is available99,139,164. We modeled the corresponding Med10 
region, which forms three helices, α1, α2 and α3, corresponding to helices α1, α2 and 
α4 in Med8139. In the head module structure, these three helices interact with 
Med11N/Med22N. In particular, Med8 helix α2 interacts with Med22 helix α2.  
Finally, two cross-links guided an approximate positioning of the external 
Med7N/Med31 subcomplex structure onto the obtained model. One cross-link was 
mapped between Med7N and a flexible linker in Med7C, and another one between 
Med7N and helix α3 in Med21. These restraints were not sufficient to ascribe a 
unique position to Med7N/Med31, but strongly suggested that this subcomplex is 
located near the Med7C/Med21 coiled-coil (Fig. 15). These results are consistent with 
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our previous notion that the Med7N/Med31 forms a surface subcomplex on 
Mediator102. 
 
Figure 15 | Model of the Mediator middle module. Subunits are shown as ribbon and 
colored as in Fig. 13. Med9 helix α1 is represented as a semi-transparent ribbon because its 
exact position remains unclear. The Cα atoms of cross-linked residues are shown as spheres. 
Colored dashed lines indicate the first ten residues extending from both termini of the model. 
Black dashed lines indicate inter-subunit or intra-subunit cross-links. The two views are 
related by a 90° rotation around a horizontal axis. 
 
3.2.4 Elongated architecture of the middle module 
Our model is in agreement with reported data for the middle module. The length of 
the model is compatible with the previously determined hydrodynamic radius of the 
module103. The elongated shape of the model is reminiscent of the recently published 
electron microscopic density of the endogenous middle module78. All subunit 
interactions observed in the model have been reported using biochemical 
methods78,96,101,103. There are only two described subunit interactions that the model 
does not account for, between Med10 and subunits Med4 and Med3178,103 but these 
interactions may be made by protein regions that could not be modeled and did not 
crosslink (Fig. 14). 
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The most notable feature of our model is its length of around 180 Å, which is 
consistent with the idea that Mediator envelopes a large surface area of Pol II. The 
model further emphasizes the flexible nature of the Mediator middle module, which 
explains why crystallization attempts were unsuccessful. The Med7C/Med21 
subcomplex contains a flexible hinge between its four-helix bundle domain and its 
coiled-coil protrusion101. The Med4/Med9 heterodimer adopts a similar fold and 
likely harbors a similar hinge. This suggests that the terminal helix bundle domains in 
the 6-subunit middle module adopt their relative orientation and distance upon 
binding of Med1 and formation of higher-order complexes. 
 
3.3 Architecture of the RNA polymerase II–Mediator core 
initiation complex 
The work presented in this chapter was published. 	  
C. Plaschka, L. Larivière, L. Wenzeck, M. Seizl, M. Hemann, D. Tegunov, E. V. 
Petrotchenko, C. H. Borchers, W. Baumeister, F. Herzog, E. Villa, P. Cramer. 
Architecture of the RNA polymerase II–Mediator core initiation complex. Nature 
(2015) 518, 376-380. 	  
To reveal how Mediator regulates transcription initiation we prepared an active, 
homogeneous, recombinant 15-subunit core Mediator (cMed) that contains the head 
and middle modules. cMed corresponds to the endogenous core Mediator purified 
from yeast67, and has a human counterpart that was reported while our manuscript 
was in revision111. cMed binds the core ITC (cITC), which lacks TFIIE and TFIIH 
and is stabilized by a short six-nucleotide RNA16,40. We resolved the architecture of 
the cITC–cMed complex by cryo-EM and protein crosslinking. Our results reveal the 
location of Mediator on Pol II and suggest mechanisms of transcription regulation. 
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Figure 16 | Reconstitution of Pol II-Mediator complex cITC–cMed. a, SDS–PAGE 
analysis of recombinant 15-subunit cMed. Head and middle module subunits are labelled in 
blue and violet, respectively. Asterisks mark essential subunits. b, Recombinant cMed is 
functional in promoter-dependent transcription, whereas head and middle modules are not 
(see 2.2.5). As a positive control, Mediator-depleted nuclear extract was complemented with 
a Mediator fraction, either TAP–Mediator or Flag elution. The RNA product was visualized by 
primer extension ins triplicate experiments. c, Assembly of the cITC–cMed complex and 
protein colour key used throughout. d, SDS–PAGE analysis of the cITC–cMed complex after 
size exclusion chromatography. 
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Figure 17 | cMed reconstitution, activities, and cITC binding. a, Schematic view of 
vectors used for co-expression of cMed. RBS, ribosome binding site; 10×His tag, 10×histidine 
tag; ori, origin of replication; lacI, gene encoding Lac repressor. Sm, Amp and Kan refer to 
streptomycin, ampicillin and kanamycin resistance genes, respectively. b, Recombinant cMed 
is active in activator-independent promoter-dependent transcription53. Compare with Fig. 
16b. c, Recombinant cMed binds purified GST–CTD fusion protein, but not GST alone that 
was immobilized on glutathione resin. An asterisk marks two contaminant bands. d, 
Recombinant cMed binds Pol II in a pull-down experiment. Pol II was immobilized on 
streptavidin resin via a biotin tag on the Rpb3 subunit. e, Recombinant cMed binds purified 
Pol II during size exclusion chromatography. Chromatograms of cMed (blue), Pol II (grey) and 
Pol II–cMed complex (magenta) are shown (top). Peak fractions of the Pol II–cMed were 
analysed by SDS–PAGE (bottom). f, Negative-stain EM image of cITC–cMed complex. The 
scale bar is 100 nm. g, Cryo-EM image of cITC–cMed complex. 
 
3.3.1 Core Mediator and electron microscopy 
We previously prepared Mediator head and middle modules by co-expression of their 
subunits in bacteria139,140. The head module comprised subunits Med6, Med8, Med11, 
Med17, Med18, Med20, and Med22. The middle module contained Med4, Med7, 
Med9, Med10, Med21, and Med31. Recombinant head and middle modules did not 
bind each other, but their co-expression with subunits Med14 (residues 1–745) and 
Med19 enabled purification of a stable cMed complex (see 2.2.5, Figs 16 and 17a). 
Med14 enabled association of the two modules, consistent with a scaffold function176. 
cMed comprised 15 conserved55 subunits (Fig. 16a), including all subunits essential 
for yeast viability21. cMed was functional in basal and activated promoter-dependent 
transcription, whereas the head and middle modules were not (Figs 16b and 17b). 
Pure cMed bound to Pol II and the CTD (Fig. 17 c-e), and to the cITC (Fig. 
16c, d). The cITC–cMed complex was stable during size exclusion chromatography 
and contained all 31 polypeptides (Fig. 16d, Supplementary Table 3). The sample 
comprised particles of the expected size when observed by EM in negative stain, and 
was used for cryo-EM data collection with a direct detection device (Fig. 17f, g; see 
2.2.5). An unbiased reference structure was generated by tomographic reconstruction 
(see 2.2.5). Unsupervised 3D classification of particle images revealed that the cITC–
cMed complex co-existed with free cITC and Pol II–DNA/RNA complex (see 2.2.5). 
We obtained high-resolution reconstructions for cITC–cMed, cITC, and Pol II–
DNA/RNA complexes at resolutions of 9.7 Å, 7.8 Å, and 6.6 Å, respectively (Figs 
18a, 19, 20, see 2.2.5). 
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Figure 18 | EM structure of Pol II initiation complex cITC. a, EM reconstruction (4,439 
particle images, 0.143 FSC = 7.8 Å resolution) with fitted structures as ribbon models. The 
views are previously defined front and top views of Pol II155. The density was filtered by local 
resolution. b, TFIIB X-ray structure14 (ribbon) explains the EM density. View is from the 
side155. c, Course of the DNA template strand through the active centre and putative non-
template strand density in the transcription bubble. View is as in b. d, TFIIF Tfg1 elements. 
The ‘charged helix’ protrudes towards downstream DNA, whereas the ‘arm’ tracks along the 
protrusion towards the upstream DNA bubble.  
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Figure 19 | Structural modelling of cITC into the cryo-EM density. a, Automatic fitting of 
structures into cITC cryo-EM density. The order of structure fitting and the corresponding 
translation correlation peaks are indicated (left). After fitting of all structures (right), the 
remaining density (cyan) was attributed mainly to DNA and TFIIF. b, Fit of TBP to the cITC 
EM density. c, Detailed views of Pol II domains foot, funnel, and clamp head in the cITC EM 
density. d, Two views of the cITC EM reconstruction corresponding to previously defined front 
and side views of Pol II155. The final cITC model is coloured (DNA template/non-template, 
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blue/cyan; RNA, red; Pol II, silver; TBP, red; TFIIB, green; TFIIF Tfg1/Tfg2, violet/magenta). 
Tfg1 and Tfg2 contain non-conserved insertions in the TFIIF dimerization module. e, The 
cITC map reveals density for the Tfg2 C-terminal linker and winged helix (WH) domain. The 
view corresponds to the side view in c, but is rotated around a vertical axis by 30°. The mobile 
Tfg2 WH domain is visible at lower density threshold. The homologous human RAP30 WH 
domain (Homo sapiens, Hs) was modelled on the basis of its position in the human initiation 
complex39 and resides at a similar location. f, The cITC map reveals density that may 
correspond to the Tfg1 N-terminus, as suggested by protein–protein crosslinking38,40. g, 
Comparison of EM densities for promoter DNA in cITC (top) and in the Pol II–DNA/RNA 
complex (bottom). The Pol II elements active site (magenta), bridge helix (green), trigger loop 
(dark red), wall (grey), and template DNA (dark blue), non-template DNA (light blue) and RNA 
(red) are depicted. h, Minor repositioning of TFIIB cyclin domains compared to our previous 
model9. i, Minor rotation of the TBP–DNA–TFIIB complex on the Pol II wall in the cITC 
structure compared to the previous open complex model40. 
 
3.3.2 cITC structure and DNA stabilization 
The cITC reconstruction enabled automated fitting of crystal structures of Pol II, 
TFIIB, TBP, and a TFIIF homology model (Figs 18a, b and 19a–c; see 2.2.5). The 
remaining EM density belonged to DNA and parts lacking from the TFIIF model 
(Figs 18c, d and 19d–g). The resulting cITC structure was consistent with a model 
derived biochemically177, and confirmed and extended our previous model14,16,40. The 
TFIIB–TBP–DNA complex resided on the Pol II wall, but was slightly rotated 
towards the Pol II protrusion compared to an earlier model40 (Fig. 19h, i). The 
previously unobserved14 TFIIB C-terminal cyclin domain bound upstream DNA and 
the Pol II protrusion and subunit Rpb12 (Fig. 18). 
The cITC reconstruction revealed the path of the DNA template through the 
Pol II cleft (Figs 18c and 19g). The template strand descended from the wall to the 
active site through the template tunnel14 lined by TFIIB and the Pol II fork loop 1 and 
rudder. At the location expected for the non-template strand178 we observed tubular 
densities (Fig. 18c). The TFIIF dimerization module resided on the Pol II lobe as in 
the Pol II–TFIIF complex38,177. The ‘charged helix’ of TFIIF subunit Tfg1 extended 
from the dimerization module to DNA at position +12 downstream of the 
transcription start site (Fig. 18d) and may stabilize loaded DNA39. The Tfg1 ‘arm’ 
extended along the Pol II protrusion towards the transcription bubble (Fig. 18d). The 
linker region of TFIIF subunit Tfg2 passed between the protrusion and TFIIB, and 
connected to the C-terminal winged helix (WH) domain located at the upstream 
bubble (Fig. 19 d, e). The cITC structure is highly conserved39, and indicated that the 
Tfg2 linker and C-terminal winged helix domain stabilize TFIIB and open DNA17. 
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3.3.3 cITC–cMed structure 
 
Figure 20 | EM structure of the cITC–cMed complex. EM reconstruction (3,267 particle 
images, 0.143 FSC = 9.7 Å resolution) viewed as in Fig. 18a with fitted structures (ribbon 
models). The density was filtered by local resolution. Mediator head and middle modules are 
coloured in blue and violet, respectively. We observe a single location of cMed on Pol II. 
Head module regions neck, fixed jaw and movable jaw are indicated. A black arrow marks the 
beginning of the linker to the Pol II CTD. 
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Figure 21 | Structural modelling of cITC–cMed into the cryo-EM density. a, Automatic 
fitting of atomic models into the cITC–cMed density. The order of model fitting and the 
corresponding translation correlation peaks are indicated (left). After fitting of all models 
(right), the remaining density (cyan) was attributed to the middle module and to some minor 
additional protein regions in the cITC and head module. b, Detailed views of Pol II domains 
foot, funnel, and clamp head in the cITC–cMed EM density. c, Fit of improved Mediator head 
crystallographic model to the corresponding cryo-EM density for cITC–cMed. The different 
head domains are depicted in different colours. Views are from the previously defined right 
side and top views of the head module139. d, The head module undergoes minor changes in 
conformation upon formation of the cITC–cMed complex. The EM fit with a modified model of 
the S. cerevisiae (Sc) Mediator head is compared to the crystal structures of head modules 
from S. pombe (Sp) (PDB code 4H63) and Sc (modified based on PDB code 4GWP). 
Previously defined top view of the head module139. 
 
The cITC model was placed unambiguously into the EM reconstruction of the cITC–
cMed complex (Figs 20 and 21a, b). The remaining density belonged to cMed and 
was 240 Å long, 120 Å high, and 110 Å wide. We observed a single location of cMed 
on Pol II that differed from previously reported locations (Fig. 20, see 2.2.5). About 
half of the cMed density corresponded to the head module, and revealed the module’s 
neck, fixed jaw, and movable jaw139,164. We fitted structures for the two jaws70,139 and 
an improved model for the S. cerevisiae neck164 based on the Schizosaccharomyces 
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pombe head module structure139 (see 2.2.5, Fig. 21c). The relative position of the neck 
and jaws was similar in the free module from S. pombe139 but differed in the S. 
cerevisiae structure99,164, indicating mobility (Fig. 21d). 
The remaining cMed density belonged to the middle module, Med14, and 
Med19. The density agreed with an extended shape of the middle module140 and was 
divided into four regions that we call hook, knob, beam, and plank domains (Fig. 20). 
The middle module was connected to the shoulder and arm of the head module as 
proposed139. Additional contacts to the joint and fixed jaw domains in the head 
module revealed an intimate head–middle module interaction, in agreement with 
recent data93,94. 
3.3.4 Mediator topology 
Since the middle module is structurally unresolved, we elucidated its subunit topology 
with protein crosslinking. For the cITC–cMed complex we obtained 706 high-
confidence lysine–lysine crosslinks that provided 243 distance restraints (Figs 22a 
and 23a-d). Our structure explained 196 crosslinks within the cITC, 26 crosslinks 
within the head module, 26 crosslinks between the head module and the remainder of 
cMed, and 21 crosslinks between cITC and cMed. Crosslinking analysis of free cMed 
provided 52 additional crosslinks (Fig. 23a-d). 
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Figure 22 | Protein crosslinking and cMed architecture. a, Overview of protein–protein 
crosslinks visualized with xiNET. Solid and dashed lines indicate crosslinks for cITC–cMed 
and free cMed, respectively. Circle area correlates with protein mass. Line thickness 
correlates to the number of crosslinks. 13 crosslinks in flexible regions that exceeded the 
27 ± 3 Å distance restraint between Ca atoms were excluded. b, Architecture of cMed and 
location of middle module subunits. Views are as defined for the head module139. Crosslinking 
residues were mapped onto the head module (red spheres) and labelled with crosslinking 
residues in the middle module. Mutants med17-158, med17-208, and med17-257 (yellow 
spheres) that cause synthetic lethality with a Pol II mutation171 map to the head–middle 
module interface. Putative locations of the Med14 N-terminal (residues 1–299) and C-terminal 
(residues 300–745) regions are indicated. 
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Figure 23 | Protein–protein crosslinking. a, Crosslinks between Pol II and TBP, TFIIB, and 
TFIIF confirm cITC architecture. Crosslinks were visualized using xiNET (Rappsilber 
laboratory). b, Crosslinks within the cMed head module and between the head module and 
Pol II. Solid lines indicate crosslinks derived from cITC–cMed data; dashed lines indicate 
additional crosslinks obtained only for free cMed. c, Crosslinks within the cMed middle 
module and between the middle module and Pol II. Crosslinks within the middle module 
agree well with the proposed middle module architecture103,140. d, Crosslinks between head 
and middle modules elucidate cMed architecture. e, Possible location of the previous model 
of the Mediator middle module (ribbons, left140) within the observed cMed density in the cITC–
cMed reconstruction based on protein crosslinking. The cITC–cMed complex is viewed from 
the ‘bottom’, which corresponds to the top view rotated by 180° around a vertical axis. 
 
The data indicated that the middle module hook and knob contained subunits 
Med7, Med10, Med19, Med21, and Med31, and that the globular Med31 domain103 
formed part of the knob (Figs 22b and 23e). The Med7–Med21 heterodimer resided 
near the arm and shoulder of the head module. The beam domain contained Med14. 
The Med14 N-terminal region (residues 1–299) resided between the middle module 
and the joint and spine domains of the head module. The Med14 C-terminal region 
(residues 300–745) crosslinked to the head module jaws. The plank contained the 
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Med4–Med9 heterodimer. This resulted in a revised cMed topology that is not 
consistent with the canonical Mediator architecture, but with the recent alternative 
Mediator topology93,94 and the architecture of the human cMed counterpart111. 
3.3.5 Initiation complex stabilization 
In the cITC–cMed structure, cMed binds around the Pol II Rpb4–Rpb7 stalk that is 
required for initiation179 and forms three interfaces with the cITC (interfaces A to C, 
Fig. 24). In interface A, the movable jaw heterodimer Med18–Med20 binds the TFIIB 
B-ribbon domain, the Pol II dock, and the Rpb3–Rpb11 heterodimer (Fig. 24a, b). 
This contact can explain Mediator-facilitated recruitment of TFIIB52 and a 
requirement of the B-ribbon for transcription180, and is consistent with SRB mutations 
in the joint and movable jaw of the head module that rescue the phenotype of the 
rpb1-14 mutant that alters the dock48. The location of Med20 between the Rpb3 zinc 
loop and Rpb3–Rpb11 dimerization domain explains why mutation of the Rpb3 zinc 
loop impairs Mediator binding171 and is consistent with two Mediator-Pol II 
crosslinks (Figs 23b, 24b and 25a). The mutant SRB2-1 comprises a point mutation in 
Med20 located in interface A (Fig. 25b), suggesting that weakening this interface 
suppresses a lethal CTD truncation47. The C-terminal region of Med14 may stabilize 
interface A because it contacts Med20 and crosslinks to Rpb11 (Figs 23c, d, 25a). 
Interface B is formed between the conserved arm domain in the head module 
and the Rpb4–Rpb7 stalk. The interaction involves the arm domain helices α1 and α2 
in Med8 and α2 in Med17139 and α-helices H*, H3, and H6 in Rpb432 (Fig. 24c). The 
EM density suggests ordering of a mobile insertion between Rpb4 helices H1 and H* 
and explains a crosslink between H1 and the joint of the head module (Fig. 24c). 
Interface C is formed between the plank domain in the middle module and the Pol II 
foot and explains a crosslink from Med9 in the plank to the foot (Fig. 24d). Interface 
C is transient because the plank is detached from the foot in a subgroup of EM 
particles (Fig. 24d). The interfaces are hydrophilic and contain conserved residues, 
suggesting a conserved Pol II–Mediator interaction. 
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Figure 24 | cITC–cMed interfaces. a, View of cITC–cMed complex from the top. Previously 
defined domains of Pol II155 and Mediator head module139 are in different colours. b, Interface 
A. Spheres depict Cα atoms of residues mutated in yeast strains SRB2-1, Rpb3-2, and Rpb1-
14. Crosslinked residues in Pol II and Med20 are indicated. c, Interface B. Secondary 
structure elements are labelled according to the previous nomenclature32,139. A crosslink from 
Rpb4 to the head module joint is indicated. d, Transient interface C. Classification of cITC–
cMed particles reveals movement of the plank domain in the middle module. Unsharpened 
maps at 22 Å resolution for classes 3 and 4 are in violet and gold, respectively 
(Supplementary Fig. 3). Crosslinks from the Pol II foot to Med9 K99 (cMed) are indicated. 
View as in Fig. 20 (top). 
 
Functional data are consistent with the observed cITC–cMed interfaces. In 
vitro, promoter recruitment of Pol II and TFIIB is lost in extracts from a srb4-ts strain, 
in which the head module dissociates from Mediator54,181. Addition of recombinant 
head module rescued this defect (Fig. 25b), consistent with previous results97 and with 
our observation that most cITC contacts are formed by the head module. Variants of 
cMed with amino-terminal truncations of Med8 perturb interface B and were strongly 
impaired in Pol II binding (Fig. 25c). In contrast, cMed variants perturbing either 
interface A (lacking the movable jaw) or interface C (lacking Med4–Med9) still 
bound Pol II, showing that interface B is critical for cMed binding to Pol II. 
Consistent with these findings, perturbation of interface A in vivo by nuclear 
depletion of Med18 led to a mild decrease in messenger RNA synthesis rates165, 
whereas perturbation of interface B by deletion of Rpb4 or dissociation of the head 
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module (interfaces A and B) resulted in a strong, global reduction of mRNA synthesis 
(Supplementary Fig. 2 and ref.182). 
 
Figure 25 | Analysis of the cITC–cMed interface. a, Crosslinks between cITC and cMed 
were mapped on available models of cITC and Mediator head module. Two views of cITC–
cMed are shown, a top view rotated by 135° around the horizontal axis and an additional 90° 
around the same axis. Mapped crosslinks exceeding the 30 Å distance restraint were 
coloured in grey. Crosslinks between lysine residues (black spheres) are labelled or connect 
(dashed magenta lines) to proximal cMed density, where plausible. Med14 N- and C-terminal 
regions are indicated. b, Immobilized template assay using nuclear extract of srb4-ts and 
wild-type yeast strains demonstrates that recruitment of Pol II and TFIIB depends on the 
Mediator head module. Schematic protocol for the immobilized template (ITA) assay100 (top). 
The loss of Pol II, TFIIB and Mediator head module from promoter DNA by heat inactivation 
of the srb4-ts nuclear extract is rescued by addition of recombinant head (rHead) module100 
(bottom). c, Pull-down assays with recombinant cMed variants carrying mutations in 
interfaces A, B, and C reveal that interface B is essential for Pol II binding, whereas interfaces 
A and C are not. For definition of interfaces see Fig. 24. The assay measures retention of 
cMed variants on Pol II coupled to beads (see Fig. 17d). Interface A was perturbed by 
deletion of the movable jaw, Med8C(residues 1–189)–Med18–Med20. Interface B was 
perturbed by removal of parts of the arm domain, either by N-terminal truncation of Med8 
(Δ1–29, deleting only the flexible N-terminal tail; Δ1–59, deleting the tail and helix α1; Δ1–87, 
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deleting the tail and helices α1 and α2), or by removal of Med6, which contributes a helix to 
the arm domain (ΔMed6). Interface C was perturbed by deletion of Med4–Med9. Shown are 
SDS–PAGE analyses (Coomassie staining). On the left, 2 µg of purified input cMed variants 
were analysed and the integrity of the complexes confirmed. The identity of the cMed variant-
specific bands was confirmed by mass spectrometry. Some minor contaminant bands are 
marked with asterisks. On the middle gel, the bead elutions after the pull-down assays are 
shown. Wild-type cMed bound to Pol II-coupled beads, providing a positive control (rightmost 
lane). cMed variants were retained by Pol II-coupled beads to various degrees. Whereas 
cMed variants with perturbations in interfaces A and C bound to Pol II, several variants with 
perturbations in interface B were impaired for Pol II binding. On the right, the bead controls 
are shown. None of the analysed cMed variants bound to beads only, providing a negative 
control. 
 
3.3.6 Pol II activation and phosphorylation 
Transcription activators located on upstream DNA can recruit Mediator by binding its 
tail module. Consistent with this, the tail module is predicted to reside near upstream 
DNA as shown by superposition of the EM density of free Mediator94 onto our 
structure (Fig. 27a). The superposition further argues that Mediator does not undergo 
major structural changes upon Pol II binding. Transcription activation may however 
include conformational control of Pol II. We propose that cMed stabilizes an active 
arrangement183 of the two major polymerase modules155 ‘core’ and ‘shelf’, because it 
bridges between these modules via interfaces A and C, respectively. Mediator may 
also communicate with TFIIS allosterically (Fig. 27b), because TFIIS reorients the 
shelf module22 that contains the foot, and cooperates with Mediator during initial 
transcription25. Mediator may also facilitate DNA opening by positioning the clamp 
and the Rpb4–Rpb7 stalk (Fig. 27c). 
We considered how Mediator may stimulate CTD phosphorylation at serine-5 
residues by TFIIH68. Comparison of our structure with the EM reconstruction of the 
human initiation complex that includes TFIIE and the core of TFIIH39 suggested that 
TFIIE reaches the head module arm and shoulder, and that the TFIIH core may bind 
the middle module (Figs 26a and 27c, d). This may explain how Mediator stabilizes 
TFIIE and TFIIH in the initiation complex20. The TFIIH kinase subcomplex, which 
was modelled onto the human complex39, projects into a ‘cradle’ formed between Pol 
II and the Mediator arm and hook domains (Figs 26a and 27b, c). A part of the CTD 
was apparently ordered inside the cradle on the surface of the arm domain at a 
location similar to that of a CTD peptide observed in head module crystals164 (Figs 
26b and 27e). Thus Mediator may stimulate CTD phosphorylation by orienting the 
mobile TFIIH kinase and CTD within the cradle, consistent with a previous 
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suggestion68. Indeed, cMed could stimulate CTD phosphorylation by TFIIH in vitro 
(Fig. 27e), although less strongly than endogenous Mediator (not shown). 
 
 
Figure 26 | Initiation complex model and CTD cradle. a, Schematic of the Pol II–Mediator 
initiation complex viewed from the top155. Locations of TFIIA, TFIIE, and TFIIH were inferred 
from the EM reconstruction of the human initiation complex39 (Fig. 27d). The location of the 
Mediator tail module was inferred from the revised Mediator architecture94 (Fig. 27a). b, View 
from the front into the ‘cradle’ of the cITC–cMed complex. A modelled CTD peptide (magenta) 
was positioned according to the head module–CTD structure164 (PDB code 4GWQ). The 
middle module is transparent. 
 
 
Results and Discussion 
 74 
 
Figure 27 | Inferred locations of the Mediator tail module, TFIIS, the general factors 
TFIIA, TFIIE, and TFIIH, and the CTD, and comparison with the human initiation 
complex. a, Superposition of revised free yeast Mediator EM reconstruction94 (transparent 
lower-resolution surface, coloured in shades of blue) onto cITC–cMed (coloured as in Fig. 
20). This reveals a high degree of similarity in the cMed region, and suggests locations of the 
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tail module and subunit Med1 that are not present in cMed. b, Modelled location of TFIIS 
(yellow) within the cITC–cMed complex based on the Pol II–TFIIS complex (PDB code 
1Y1V)22. c, Movement of the Rpb4–Rpb7 stalk upon cMed binding to the cITC and location of 
the ‘cradle’. Two views of the S. cerevisiae (Sc) cITC–cMed complex related by a 180 degree 
rotation around a vertical axis. The left view corresponds to the previously defined top view of 
Pol II155. The box contains a zoom-in view of the Rpb4–Rpb7 complex revealing its movement 
upon cMed binding. The right view reveals the location of the ‘cradle’ on the ‘bottom’ of Pol II. 
The density is transparent, with the final cITC-head module model underneath and coloured 
(DNA template/non-template, blue/cyan; RNA, red; Pol II, silver; TBP, red; TFIIB, green; TFIIF 
Tfg1/Tfg2, violet/magenta; head module, blue; middle module, violet). d, Human (Homo 
sapiens, Hs) initiation complex EM reconstruction39 viewed as in a. The complex reveals 
equivalent locations for TFIIB, TBP, TFIIF, and DNA, and additionally contains TFIIA (yellow), 
TFIIE (magenta), and the core subcomplex of TFIIH (solid orange surface) and a modelled 
TFIIH kinase subcomplex (orange mesh). e, Putative density for the CTD (magenta) near a 
modelled peptide (black) positioned according to the head module-CTD complex co-crystal 
structure (PDB code 4GWQ). The putative density superposes moderately well with the 
modelled CTD peptide and suggests the CTD may adopt a different conformation in cITC–
cMed with respect to the binary head module–CTD complex. This density cannot be assigned 
to the CTD with certainty because it may also stem from unresolved protein regions in 
Mediator. Coloured as in Fig. 24a. The region C-terminal of the CTD remained flexible and 
crosslinked to distant proteins (not shown, see Fig. 23). f, Recombinant cMed stimulates 
TFIIH kinase activity, whereas the free head and middle modules do not. The relative activity 
(rel act) of Pol II phosphorylation at CTD residue serine-5 (S5P) was determined with respect 
to background (Rpb3). 
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4. Conclusions and Outlook 
This thesis covers structural and functional studies of the Mediator complex and its 
role in Pol II transcription regulation. We determined the 3.4 Å crystal structure of 
the 6-subunit Sp Mediator head module that constitutes one half of the conserved and 
essential core Mediator (Fig. 6). New structural and mobile elements were identified 
that confirm and extend previous mutational and structural analysis of Mediator sub-
complexes21 and revised models of the Sc head module at 4.2-4.3 Å resolution99,164. 
Protein crosslinking of the recombinant 6-subunit Mediator middle module led to a 
first architectural model of this second half of core Mediator (Fig. 15). Finally, we 
prepared a recombinant 15-subunit core Mediator, which contained the complete 7-
subunit head module, the 6-subunit middle module, and subunits Med19 and Med14. 
Med14 bridges the two modules, whereas Med19 increased yield. Core Mediator was 
active in basal and activated transcription, and bound to a Pol II core initially 
transcribing complex (cITC) that further contained the general factors TBP, TFIIB, 
TFIIF, and promoter DNA. 
Cryo-EM of the cITC elucidated the evolutionarily conserved core initiation 
complex and revealed functions of general transcription factors (Fig. 18). We 
determined the complete path of the DNA template strand and TFIIF elements that 
reach into the Pol II cleft, likely to stabilize DNA. Cryo-EM and protein crosslinking 
of the cITC-core Mediator complex agreed with a revised Mediator 
architecture93,94 and revealed a single position of cMed on Pol II that is different from 
previous studies21,94 (Fig. 20). The cITC-Mediator core architecture suggests how 
Mediator interacts with transcription activators bound to upstream DNA, stabilizes the 
initiation complex, stimulates Pol II activation and CTD phosphorylation. In 
particular, the location of the tail module was inferred by crosslinking (Figs 23 and 
24a) and EM of free Sc Mediator93,94 that suggests close spatial proximity of the 
Mediator tail module to the average transcription factor binding site 250 
basepairs184 upstream of the transcription start site. Our results reveal that only minor 
adjustments in Mediator structure are required to bind Pol II (Fig. 27a), in contrast to 
earlier findings21,94. This indicates that the interaction of Mediator with the initiation 
complex relies on co-operative binding of Pol II and general factors60 rather than 
Mediator unfolding185.  
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Mediator control may carry an allosteric component. Mediator and TFIIS 
cooperate during transcription initation25, and may communicate through the Pol II 
foot and the Mediator plank domain that contains Med1, Med4, and Med9. Core 
Mediator did not contain Med1, and may be added in an ongoing effort to prepare a 
complete recombinant Mediator complex. Mediator may influence Pol II 
conformation since it bridges the Pol II ‘shelf’ and ‘core’ modules and affects the Pol 
II stalk position (Fig. 27c). Thereby Mediator may assist in stabilization of the Pol II 
clamp, DNA loading, and recruitment of additional factors. These regulatory 
strategies may extend to other transcription systems. For example the Pol I-specific 
factor Rrn3 binds Pol I in the region corresponding to interfaces A and B (Fig. 24a) 
and may stabilize the TFIIB-like factor Rrn7186 together with Rrn6187. This work 
further explains mutational and genetic data on the head module, and their impact on 
initiation complex formation (Figs 12, 24, and 25). We provide evidence that 
Mediator is a global (Supplementary Fig. 2) and basal (Fig. 6a) regulator of 
transcription, in agreement with previous studies53,54. In summary, these results 
contribute to a structural and functional framework of the conserved mechanism of 
transcription initiation in eukaryotes (Table 1). 
Many questions regarding transcription initiation remain. What is the structure 
and function of the remaining Mediator tail and kinase module subunits? Do 
transcription activators influence Mediator tail module structure or inter-module 
contacts? How do they affect transcriptional output? Little structural information is 
available for tail and kinase modules and their subcomplexes (see 1.2.3), yet they may 
be important pivots of Mediator control. Transcription activators may affect 
yeast94 and human188 Mediator conformation, yet a detailed understanding is lacking. 
The kinase module may inhibit initiation by competing with the Pol II CTD to bind 
Mediator78. Additionally, the kinase module may occlude the Pol II binding site on 
Mediator through a steric or allosteric mechanism. However, the kinase module may 
also have an activating function80. For example, the cdk8 kinase can activate 
transcription factors, such as the oncogenic beta-catenin189. The kinase module further 
influences Mediator recruitment, for example through associated activating non-
coding RNA in human cells190. It will be important to extend recombinant expression 
of core Mediator established here to tail and kinase modules to enable structural and 
functional analysis.  
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How are Pol II, Mediator and GTFs released during Pol II promoter 
escape? Mediator may remain on Pol II after promoter escape, because modelling 
suggests it neither interferes with RNA exit or with binding of the elongation factors 
TFIIS22 and Spt4/5191. Pulldown experiments suggest that Pol II, in vitro phos-
phorylated at residue Ser5 of the CTD, does not inhibit the binary Pol II-Mediator 
core interaction (Plaschka et al., unpublished), in contrast to pulldowns using 
heterogeneous endogenous proteins68. Mediator association with the initiation 
complex is transient in vivo and was shown to depend on kinase activity of the general 
factor TFIIH184,192. Therefore, promoter escape may depend on the combined force of 
a transcribing Pol II193, nascent RNA and CTD phosphorylation. The nascent 
transcript assists TFIIB release and facilitates formation of the elongation complex. 
CTD phosphorylation enables the recruitment of elongation factors that disrupt the 
Pol II-Mediator interaction and facilitate transcription elongation. 
What are the structures of the general factors TFIID, -IIE and -IIH? How do 
these co-operate among themselves and with Mediator to form the complete 
transcription initiation complex? Does Mediator assist in DNA melting and loading 
into the Pol II active site? Sc TFIID has a molecular mass of 1.2 MDa and consists of 
14 subunits43. Future work may reveal the structure of this flexible194 complex, how 
the observed co-operativity with Mediator is achieved69, and how the +1 nucleosome 
regulates the initiation complex195. The 10-subunit TFIIH will remain of great interest 
due to its role in promoter opening, CTD phosphorylation, and DNA repair. We 
anticipate important contacts between the core Mediator ‘cradle’ and TFIIH to 
stimulate CTD phosphorylation and possibly DNA melting. TFIIE is a core GTF that 
together with TFIIB and TBP is conserved from archea to eukaryotes1, yet its 
underlying mechanism remains unknown. TFIIE makes contact with the Pol II clamp 
domain18 and may cooperate with Mediator since the TFIIE Zn-ribbon domain binds 
to the Pol II stalk domain, which is repositioned by Mediator (Fig. 27c).  
How does Mediator influence chromatin architecture? The cohesin complex 
regulates genome architecture and showed significant interaction with human 
Mediator by pulldown coupled to mass spectrometry75. This cohesin-Mediator contact 
was confirmed by co-IP and ChIP experiments in a mouse cell line and revealed that 
this interaction is crucial to maintain enhancer-promoter chromatin architecture61. 
Future studies on Mediator may therefore look into the many additional regulators 
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that interact with Mediator and tune transcription output, for example factors involved 
in RNA processing, chromatin maintenance and modification, and DNA repair75. 
Answers to these many questions will require assembly of the complete 
transcription initiation complex. This goal will benefit from strategies established 
here. However, to fully unravel the molecular details of transcription requires the 
continued development of strategies to reconstitute transient macromolecular 
complexes, to integrate structural biology and single-molecule methods, and to apply 
functional in vitro and in vivo techniques. The final challenge will be to integrate all 
available data into a single model that can explain and predict how the cell controls 
gene transcription. 
  
Structural biology will continue to play a central role in deciphering the cell’s inner 
workings. For more than half a century macromolecular X-ray crystallography has 
delivered key insights into biology115. Automation from crystallization to data 
processing, new third generation beamlines, the free-electron laser and electron 
diffraction experiments are likely to push the limits of crystallography even further. 
Mass spectrometry has made great contributions to integrated structural biology with 
the advent of protein crosslinking, hydrogen-deuterium exchange, surface 
modification and protein-RNA crosslinking196. Importantly, we should aim to 
integrate available mass spectrometry software into a single package that serves the 
community analogous to the collaborative computational project No. 4 (CCP4). 
Further, we should continue development of a mass spectrometry data bank197 and 
encourage scientists to share published data with the community. 
We may expect the greatest progress in EM. Improved imaging hardware and 
processing software have enabled a ‘resolution revolution’116 in EM. Even 
asymmetric macromolecules of a molecular weight less than 0.5 MDa can now yield 
sub-nanometer and even near-atomic resolution198. These new developments will 
make single particle analysis a routine method of structure determination. In parallel, 
cryo-electron tomography permits the study of protein complexes in their native 
cellular environment. A recent breakthrough demonstrates the promise of this 
technique199. By the combined use of a new type of phase plate and direct detection 
device, the Baumeister group was able to quantitatively study conformational states of 
the 26S proteasome in neuronal cells199. This technique may reveal nuclear chromatin 
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structure, enhancer-promoter contacts, and gene looping, in short, the in situ structure 
of a gene.  
It will require a combined national and international effort, to make EM 
facilities easily accessible and to facilitate software and hardware developments. It 
will be paramount to improve software that automates operation of the EM 
microscope and imaging hardware, to increase the throughput of biological samples. 
Great progress has been made, through for example open-source projects such as 
TOM2 (ref.146) or LEGINON200 that control the microscope and enable automated 
data acquisition. Automatic alignment of several orders of astigmatism has been 
achieved on a CS-corrected microscope201. Image analysis will continue to improve 
and benefit from a communal effort, such as the recently established CCPEM 
project202, closely modelled on CCP4. 
Combining these orthogonal structural and system-wide data will require 
continued development of integrated modelling platforms203. Most importantly, we 
must continue to support a coordinated and communal research infrastructure and 
enable scientific discovery. 
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Supplementary Figure 1 | Conserved primary and secondary structure of head module 
subunits. Amino acid sequence alignments for Mediator head subunits Med6, Med8, Med11, 
Med22, Med17, Med18, and Med20 from Schizosaccharomyces pombe (Sp, top), and 
Saccharomyces cerevisiae (Sc, bottom). Sequence identity between Sp and Sc subunits is 
indicated in brackets next to the protein name. Secondary structure elements are indicated 
above and below the sequences as observed in the Sp head module structure and the Sc 
backbone model, respectively (spirals, α-helices and 310/η-helices; arrows, β-strands; 
dashed lines, disordered regions; dots, not present in protein variant). Regions for which high-
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resolution structures are available are highlighted in grey over the secondary structure 
elements. Residues that are invariant or conserved among the yeasts Sp, Sc, Candida 
glabrata, Candida albicans, Ashbya gossypii, Kluyveromyces lactis, and Debaryomyces 
hansenii are highlighted in green or yellow, respectively. Subunit names are given in a colour 
code that is used throughout (Med6, yellow; Med8, orange; Med11, brown; Med22, cyan; 
Med17, green; Med18, blue; Med20, magenta). Portions of the sequences forming the eight 
structural elements of the head module are highlighted in eight different colours (domain 
colour key in Fig. 3). Spheres indicate known mutation sites (med6-ts1169, med6-ts2169, med6-
ts6169, MED6-101170, med11-ts1100, G92S20, srb4-13849,97, SRB4-101169, med17-68171, 
med17-158171, med17-208171, med17-257171, med17-327171, med22-ts1100, Hs L371P168, 
T31A20, L66P20, SRB4-148, med17-sup1171, SRB5-148, SRB2-147, SRB6-148, SRB6-201170) 
and are coloured according to their predicted effect (intrasubunit stability, yellow; intersubunit 
stability, red; unknown effect, cyan; suppressor of CTD truncation, orange; mutations 
affecting TFIIH interaction, dark blue; mutations affecting Pol II core interaction, magenta). 	  	  
Supplementary Table 1 | Data collection and refinement statistics for Med6 and 
Med17C/Med11C/Med22C crystals. 
 Med6 (native) Med6 (SeMet) Med17C/Med11C/Med22C (SeMet) 
Data collection    
Space group P213 P213 R32 
Cell dimensions      
    a, b, c (Å) 126.0, 126.0, 126.0 125.0, 125.0, 125.0 261.2, 261.2, 47.7 
Wavelength (Å) 0.91890 0.97960 0.97972 
Resolution (Å)† 2.7 (2.77-2.70)* 3.4 (3.49-3.40) 3.0 (3.08-3.00) 
CC1/2‡ 100.0 (32.4) – 99.9 (17.1) 
Completeness (%) 100.0 (100.0) 100.0 (100.0) 99.9 (100.0) 
Redundancy 20.0 (19.3) 10.4 (10.4) 5.1 (5.2) 
Rmerge (%) 5.2 (1010.2) 16.6 (145.1) 6.1 (692.2) 
I/σI 41.4 (0.6) 11.8 (2.4) 16.5 (0.6) 
    
Refinement    
Resolution (Å) 89–2.7  65–3.0 
No. reflections 18562  12487 
Rwork/Rfree 18.1/21.7  20.4/22.8 
No. atoms    
    Protein 2254  2547 
    Ligand   12 
B-factors    
    Protein 136  151 
    Ligand   190 
R.m.s deviations    
    Bond lengths (Å)  0.006  0.007 
    Bond angles (°) 0.967  1.221 
*Highest resolution shell is shown in parenthesis. 
†Resolution limits are provided using the CC1/2 > 10% criterion125. Using the traditional criterion of I/σI > 2.0, 
resolution limits are 2.9 Å and 3.2 Å for Med6 and Med17C/11C/22C crystals, respectively. 
‡CC1/2 = percentage of correlation between intensities from random half-datasets125	  	  
 
Supplementary Table 2 | Mediator head module mutations, their location, and predicted effect. 
Yeast strain Site(s) in Sc (Sp) Location  Predicted effect Ref. 
med6-ts1 F31S (F37) Med6, shoulder Fold destabilization 169 
med6-ts2 Q49L (Q55) Med6, shoulder Fold destabilization 169 
 I68L (α3-α4) Med6, shoulder  Unknown  
 L94P (α3-α4) Med6, shoulder  Unknown  
 F125Y (L88) Med6, shoulder Intersubunit destabilization   
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 R132G (N95) Med6, shoulder Fold destabilization  
 F194L (Y149) Med6, finger Intersubunit destabilization  
med6-ts6 L28P (L34) Med6, shoulder Fold destabilization 169 
 K47T (K53) Med6, shoulder Fold destabilization  
 T134A (L97) Med6, shoulder Unknown  
 Q171R (A126) Med6, shoulder Intersubunit destabilization  
 T177M (A132) Med6, arm Intersubunit destabilization  
 M273L (β7-C-term) Med6 (n/a) Unknown  
 I275V (β7-C-term) Med6 (n/a) Unknown  
MED6-101 D152Y (V107) Med6, shoulder Intersubunit stabilization 170 
med11-ts1  E17K (E28) Med11, spine Intersubunit destabilization 100 
 L24K (L35) Med11, spine Intersubunit destabilization  
T31A* T31A (I42) Med11, spine Intersubunit destabilization  20 
L66P* L66P (L72) Med11, spine Fold destabilization 20 
G92S* G92S (Y95) Med11, joint Intersubunit destabilization 20 
srb4-138 L21S (L18) Med17 (n/a) Not required for ts  49,97 
 N24I (E21) Med17 (n/a) Unknown  
 L124M (L56) Med17 (n/a) Not required for ts   
 S226P (S127) Med17, arm Fold destabilization  
 M313I (V209) Med17, spine Unknown  
 E460G (T329) Med17, tooth Fold destabilization  
 E583G (β11-α7) Med17, nose Unknown  
 F649S (D513) Med17, nose Fold destabilization  
SRB4-1 G353C (G242) Med17, joint Intersubunit stabilization 48 
SRB4-101 E286K (S182) Med17, spine Intersubunit stabilization 169 
med17-68 P370S (S257) Med17, joint Fold destabilization 171 
 L441P (I310) Med17, tooth Fold destabilization  
med17-158  F159Y (N-term-α1) Med17 (n/a) Unknown 171 
 S226T (S127) Med17, arm Fold destabilization  
 K280M (K176) Med17, spine Intersubunit destabilization  
 K377N (β5-β6) Med17, joint  Unknown  
 E438G (E307) Med17, tooth Fold destabilization  
 V465E (I333) Med17, tooth Fold destabilization  
med17-208 N611H (N476) Med17, nose Unknown 171 
 A655T (β14-β15) Med17, nose  Unknown  
 E669D (E525) Med17, nose Unknown  
med17-257 L520S (D405) Med17, tooth Intersubunit destabilization 171 
 I541K (I424) Med17, nose Fold destabilization  
 E669G (E525) Med17, nose Unknown  
med17-327 M442V (W311) Med17, tooth Fold destabilization 171 
 V670E (V526) Med17, nose Fold destabilization  
med17-sup1 I128V (L60) Med17 (n/a) Unknown 171 
 R582G (β11-α7) Med17, nose  Unknown  
 N595D (P459) Med17, tooth  Unkonwn  
SRB5-1 T22I (S21) Med18, movable jaw Intersubunit stabilization 48 
SRB2-1 P14H (A15) Med20, movable jaw Unknown 47 
SRB6-1 N86K (N84) Med22, spine Intersubunit stabilization 48 
med22-ts1 L73E (L71) Med22, spine Intersubunit destabilization 100 
 K80E (K78) Med22, spine Intersubunit destabilization  
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SRB6-201 N59H (E57) Med22, spine Intersubunit stabilization 47 
Human Site in Hs (Sc, Sp) Location Predicted effect Ref. 
Hs L371P L371P (M504, L389) Med17, tooth Fold destabilization 168 
Sc, Saccharomyces cerevisiae; Sp, Schizosaccharomyces pombe; Hs, Homo sapiens; Ref., Reference. 
Residues with no equivalent in Sp were annotated by the N- and C-terminal secondary structure elements closest 
to that residue (‘secondary structure’-‘secondary structure’). When mutations fell within three amino acids of the 
built Sc or Sp models, they were included in Fig. 12a or 12b, respectively for illustrative purposes. 
* Med11 mutations were numbered according to the corrected annotation100. T31A, L66P and G92S refer to 
T47A, L82P and G108S, respectively in the original publication20. 	  
Supplementary Table 3 | Components of the cITC-cMed complex. 
 Protein subunits Length (aa) Molecular weight (kDa) 
   RNA polymerase II Rpb1 1733 191.6 
 Rpb2 1224 138.8 
 Rpb3‡ 318 35.3 
 Rpb4 221 25.4 
 Rpb5 215 25.1 
 Rpb6 155 17.9 
 Rpb7 171 19.1 
 Rpb8 146 16.5 
 Rpb9 122 14.3 
 Rpb10 70 8.3 
 Rpb11 120 13.6 
 Rpb12 70 7.7 
General initiation factors TFIIB‡ 345 38.2 
 TBP‡ 61-240 20.2 
 Tfg1*‡ 734 82.3 
 Tfg2 400 46.6 
Mediator head module Med6 295 32.8 
 Med8 222 25.3 
 Med11 115 13.3 
 Med17 687 78.5 
 Med18 307 34.3 
 Med20 210 22.9 
 Med22 121 13.7 
Mediator middle module Med4 284 32.2 
 Med7 222 25.6 
 Med9 149 17.4 
 Med10 157 17.9 
 Med21 140 16.1 
 Med31 127 14.7 
Mediator (other subunits) Med14† 745 84.6 
 Med19 220 24.9 
Total 31 subunits 10,220 1,155.1 
Nucleic acid strands  Length (nt) Molecular weight (kDa) 
Template  DNA 72 22.2 
Non-template DNA 72 22.5 
Initial transcript RNA 6 2.1 
aa, amino acids; nt, nucleotides; kDa, kilo Dalton. 
*Tfg1 was from S. mikatae37. 
†Med14 construct contains an additional N-terminal 10xHis tag. 
‡Constructs contain an N- or C-terminal 6xHis tag as described40. 
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Supplementary Figure 2 | Global requirement of the Mediator head module for 
transcription. a, Fold changes in RNA degradation (log folds, x-axis) and synthesis (log 
folds, y-axis) rates observed in strains srb4-ts versus wild-type in the absence of heat shock. 
Each point corresponds to one mRNA and the density of points is reflected in their brightness. 
Red contour lines define regions of equal intensity. The centre of the distribution results from 
the median synthesis and degradation rates, whose relative contributions are indicated by 
shifts of the red lines parallel to synthesis or degradation rate axis, respectively. b, Global 
shutdown of RNA synthesis upon heat shock (HS) of the srb4-ts mutant. Fold changes in 
degradation (log fold, x-axis) and synthesis (log folds, y-axis) rates of srb4-ts and wild-type 
strains are indicated, after 18 or 60 min of HS treatment, respectively. c, As for a, but using a 
Med18-anchor-away (AA) strain in absence of rapamycin (rap) treatment. d, Global down 
regulation of RNA synthesis upon anchor-away of the Med18 subunit, after 18 or 60 min of 
rapamycin (rap) treatment, as in b. 	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Supplementary Figure 3 | 3D classification of negative-stain and cryo-EM data. a, 3D 
classification of the negative-stain EM data set into four classes. The percentage of data in 
each class is given in parenthesis. To help visualize structural differences, all 3D 
reconstructions were radially coloured in UCSF Chimera. b, Pseudo-hierarchical 3D 
classification of the cryo-EM data set. The percentage of the data in each class is given in 
parentheses. Rejects refer to EM reconstructions that did not reflect the known structures of 
Pol II, cITC or cITC–cMed. §, class of partial cITC–cMed particles lacking upstream DNA–
TFIIF–TFIIB–TBP; +, class of partial cITC–cMed particles lacking upstream DNA–TFIIB–TBP 
and the mobile plank of cMed; *, class of cITC particles that do not average well with the main 
cITC class; †, class of Pol II–DNA/RNA particles lacking Rpb4–Rpb7. cITC–cMed(a) and 
cITC–cMed(b) classes from Round 3a correspond respectively to class 3 and class 4 
superimposed in Fig. 24d. The Pol II–TFIIF class (Round 6) presented with density for the 
TFIIF dimerization module and the Tfg1 ‘charged helix’, but weak to no density for Tfg1 ‘arm’ 
and Tfg2 ‘linker’ regions due to the absence of upstream DNA stabilizing factors TFIIB and 
TBP. Classes were visualized as in a. c, 3D classification of particles from rejects of round 1 
using the Pol II–DNA/RNA reconstruction as initial model. Particles were sorted into eight 
groups, resulting in poor 3D reconstructions. Classes were visualized as in a. d, 3D 
classification of particles from class 4 of round 1 using the Pol II–DNA/RNA reconstruction as 
initial model. Particles were sorted into four groups, resulting in EM reconstructions of cITC 
and cITC–cMed. These results suggest high data quality, and further the presence of a single 
detectable cITC–cMed conformation in the cryo-EM data, even in absence of a cITC–cMed 
reference. Classes were visualized as in a. 
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Supplementary Figure 4 | Negative stain and cryo-EM reconstructions of Pol II–
DNA/RNA, cITC, and cITC–cMed complexes. a, Four views of the negative-stain 
tomography reconstruction of the cITC–cMed related by 90° rotation, starting from the 
previously defined front view of Pol II155. b, Comparison of five reference-free 2D class 
averages calculated from all particles used in the final negative-stain single-particle 
reconstruction with corresponding forward projections of the reconstruction. c, Orientational 
distribution plot of all particles in the final negative-stain single-particle reconstruction. The 
estimated angular accuracy is 3.2°. d, Fourier shell correlation of the final negative-stain 
single-particle cITC–cMed reconstruction (0.143 FSC = 25.2 Å resolution bin). e, Four views 
of the negative-stain single-particle reconstruction of the cITC–cMed related by 90° rotation, 
starting from the previously defined front view of Pol II155. f, Comparison of five reference-free 
2D class averages calculated from all particles used in the final Pol II–DNA/RNA cryo-EM 
single-particle reconstruction with corresponding forward projections of the reconstruction. g, 
Orientational distribution plot of all particles in the final cryo-EM Pol II–DNA/RNA single-
particle reconstruction. The estimated angular accuracy is 3.2°. h, Fourier shell correlation of 
the final Pol II–DNA/RNA cryo-EM single-particle reconstruction (FSC = 0.143). i, Two views 
of the Pol II–DNA/RNA cryo-EM map are shown from the previously defined front view of Pol 
II155 and rotated by 180°, and are coloured by local resolution. j, Two views of the Pol II–
DNA/RNA cryo-EM map are shown from the previously defined front view of Pol II155 and 
rotated by 180°, and are coloured by variance (the standard deviation, StdDev, of the 
normalized intensity value). k–o, As f–j but for the cITC reconstruction. p–t, As f–j but for the 
cITC–cMed reconstruction. 
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TFII  Transcription factor II  
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